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2.  LIST OF ABBREVIATIONS 
 
5CSRTT – Five-Choice Serial Reaction Time Test 
ADH – Antidiuretic hormone 
ADHD – Attention-deficit/hyperactivity disorder 
ADP – Adenosine diphosphate 
AED – Acute energy depletion 
aEEG – Amplitude-integrated EEG 
AIF – Apoptosis inducing factor 
AMP – Adenosine monophosphate 
Apaf-1 – Apoptotic protease-activating factor−1  
ATP – Adenosine triphosphate 
AVP – Arginine vasopressin 
β-NTP – β-nucleotide triphosphate 
BAK – Bcl2-antagonist/killer1 
BAT – Brown adipose tissue 
BAX – Bcl2-associated × protein 
Bcl2 – B-cell lymphoma 2 protein family 
Bcl-XL – B-cell lymphoma-extra-large 
BID – BH3 interacting-domain death agonist 
bpm – Beats per minute 
CA – Cornu ammonis 
CBF – Cerebral blood flow 
CNS – Central nervous system 
CI – Confidence interval 
CP – Cerebral palsy 
Cx - Cortex 
DAB - 3,3'-Diaminobenzidine 
DD – Delayed Discounting 
DG – Dentate gyrus 




EAA – Excitatory amino acid 
EPM – Elevated Plus Maze 
EPP – Exchangeable phosphate pool 
FiO2 – Fraction of inspired oxygen 
HC - Hippoxampus 
HI – Hypoxia-ischemia 
HIE – Hypoxic-ischemic encephalopathy 
HR – Heart rate 
IBA-1 – Ionized calcium-binding adapter molecule 1 
ICAM – Intercellular adhesion molecule 
IL – Infralimbic cortex 
ITI – Intertrial interval 
LH – Limited hold period 
MABP – Mean arterial blood pressure 
MRI – Magnetic resonance imaging 
MRS – Magnetic resonance spectroscopy 
MWM – Morris Water Maze test 
NAA – N-acetyl-aspartate 
NE – Neonatal encephalopathy 
NF-κB – Nuclear factor kappa-light-chain-enhancer of activated B cells 
NO – Nitric oxide 
nNOS – Neuronal nitric oxide synthase 
NTP – Nucleoside triphosphate 
OF – Open Field 
OFR – Oxygen free radical 
31P-MRS – Phosphorus-31 Magnetic Resonance Spectroscopy 
PaO2 – Arterial partial pressure of oxygen 
PaCO2 – Arterial partial pressure of carbon dioxide 
PBS – Phosphate-buffered saline 
PCr - Phosphocreatine 
PFA – Paraformaldehyde 




Pi – Inorganic phosphate 
PrL – Prelimbic cortex 
RI – Resident-Intruder test 
RNS – Reactive nitrogen species 
RSG Cx – Granular part of the Retrosplenial Cortex 
SD – Standard Deviation 
SEF – Secondary energy failure 
SEM – Standard Error of Mean 
SI – Social Interaction test 
Smac – Second mitochondria-derived activator of caspase 
tBID – Truncated BH3 interacting-domain death agonist  
TNF – Tumor necrosis factor 
TO – Timeout period 
TRAIL – TNF-related apoptosis-inducing ligand receptor 
Trec – Rectal temperature 
VGAT – Vesicular GABA transporter 




3.  INTRODUCTION 
 
3.1 Neonatal hypoxic-ischemic encephalopathy (HIE) 
 
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the most devastating 
diseases of the perinatal period. Approximately 1-2 newborns per 1000 live births are 
affected in the developed countries while its prevalence in the developing world is much 
higher, altogether amounting to around 700.000 neonatal deaths worldwide annually.1 
An additional 1.15 million newborns are estimated to develop neonatal encephalopathy 
and almost half a million will suffer lifelong neurodevelopmental impairments due to 
HIE.1 These children present an enormous socio-economic burden to the families and to 
the whole of society as well. Looking at only cerebral palsy (CP) which is traditionally 
considered one of the most pervasive neurodevelopmental disorders related to perinatal 
hypoxic events, it can be estimated that HIE introduces a lifelong economic burden of 
$1.9 billion every year in the US alone.2 These statistics unambiguously show that 
neonatal HIE presents one of the most severe problems in perinatal care. 
 Our definitions of “birth asphyxia” and neonatal HIE have evolved in parallel 
with our understanding of these conditions over the past few decades. Originally “birth 
asphyxia” was the umbrella term used for all cases of depressed birth, whether a mild 
and transitory respiratory problem or genuine neonatal stillbirth.3 Additionally, from the 
middle of the 19th century such a broad diagnosis was thought to be causally linked to 
the development of CP in later childhood.4 This one-dimensional causal association 
have been called into question repeatedly5 and it has become clear that in order to 
efficiently design therapeutic interventions, the diagnostic criteria need to be more 
specific. In order to avoid confusion, it might be desirable to retain the term “birth 
asphyxia” for its literal meaning, i.e. a combination of (arterial) hypoxemia and 
hypercapnia present at birth. For the neonatal condition associated with certain cases of 
birth asphyxia, there is an ongoing debate whether hypoxic-ischemic encephalopathy 
(HIE), neonatal encephalopathy (NE), or some other term would be most adequate.6 




which is outlined in Table 1. 
 
Table 1: Diagnostic criteria of hypoxic-ischemic encephalopathy.7 
A) Infants ≥ 36 completed 
weeks gestation admitted to 
the NICU with at least one of 
the following: 
• Apgar score of ≤ 5 at 10 minutes after birth 
• Continued need for resuscitation, including 
endotracheal or mask ventilation, at 10 minutes after 
birth 
• Acidosis within 60 minutes of birth (defined as any 
occurrence of umbilical cord, arterial or capillary pH < 
7.00) 
• Base Deficit ≥ 16 mmol/L in umbilical cord or any 
blood sample (arterial, venous or capillary) within 60 
minutes of birth 
B) Moderate to severe 
encephalopathy, consisting of 
altered state of consciousness 
(lethargy, stupor or coma) 




• abnormal reflexes including oculomotor or pupillary 
abnormalities 
• absent or weak suck 
• clinical seizures 
 
 HIE indicates infants, who fulfil two sets of criteria. The first category is related 
to the newborn's condition at birth (asphyxia, A criteria), including various markers of 
intrauterine or intrapartum hypoxia and a need for cardiorespiratory support. The second 
set of criteria is related to the infant's condition in the first hours after birth 
(encephalopathy, B criteria), i.e. whether neurological impairment can be observed 
following resuscitation and stabilization. Some clinical trials have employed a third set 
of criteria, which included abnormalities on amplitude-integrated EEG (aEEG),7 but in 
current clinical practice the diagnosis of HIE can be given without aEEG recording.8  
 Thus the definition of HIE is now rather narrow, compared to the historical use 
of birth asphyxia. On the one hand, infants who develop neonatal encephalopathy or CP 




A criteria) are excluded, as the underlying cause of their impairment is likely to have 
been present prior to birth, e.g. genetic causes or placental insufficiency.5 On the other 
hand, approximately 10% of all newborns require some form of assistance at birth and 
1% need vigorous cardiopulmonary resuscitation, but the majority of these infants do 
not develop encephalopathy or other neurological impairments later on.9 Thus the term 
HIE is used for infants, who demonstrably suffer from some level of neurological 
impairment in the first few hours of life and this is likely related to peripartum hypoxic 
events. 
 Historically, infants with HIE have had a highly variable prognosis. 
Approximately 35% of these infants died, 35% suffered some form of 
neurodevelopmental impairment and 30% survived with normal neurological 
outcome.10 Neurodevelopmental impairment is generally measured at 18 to 24 months 
of age, when mental and psychomotor development can already be assessed 
adequately.11 However, the majority of children showing impaired neurological function 
at 2 years also display lower IQ-scores in school age.12 
 It is important to note that while infants with moderate to severe HIE have a 
highly variable prognosis, there is an even larger group of babies, who require some 
assistance at birth, but do not develop acute encephalopathy.9 These newborns have a 
highly favorable prognosis in terms of the severe neurodevelopmental impairments of 
asphyxic babies. However, a number of cohort studies have attempted to follow these 
newborns and some have suggested an increased risk for subtle neurodevelopmental 
impairments in later life.13-17 
 
3.2 Animal models of neonatal HIE 
 
In order to design rational therapeutic interventions for neonatal HIE, it was necessary 
to develop a working understanding of its pathomechanisms.18 Due to the imprecise 
timing of hypoxia, ischemia and hypercapnia in the peripartum period, as well as to the 
difficulties of indirectly measuring the severity of encephalopathy in newborns, most of 
the mechanistic understanding of HIE emerged from animal models.19 From 1955 to 




earliest recorded experiments of neonatal asphyxia were conducted 1813 by LeGallois, 
who noted that respiratory efforts in newborn rabbits subjected to asphyxia persisted for 
27 minutes compared to only 2 minutes in adult animals.21 In 1870 Bert et al. made 
similar observations when comparing newborn pups with 20-day-old juvenile rats.22 In 
addition to the inverse correlation between maturity and tolerance to asphyxia, some of 
the earliest observations on various animal species concluded that males are less tolerant 
to asphyxia than females and high temperature, thyroxin, insulin injection or 
adrenalectomy all reduce resistance to hypoxia.23  
 In order to draw adequate conclusions from animal experiments, one needs to 
take into account a wide range of considerations regarding animal species, post-
conceptual age, level of maturity and the method of inducing hypoxia or asphyxia. 
Some of the most frequently used animal species in investigations of HIE have 
traditionally been the immature rat24 or mouse,25 the newborn piglet,26 the fetal sheep27 
and various species of non-human primates.28 The optimal age of the animal at the time 
of hypoxia depends on the developmental dynamics of the specific species as well as 
the focus of the investigation. The developmental timing of particular markers of brain 
maturity (eg. brain growth spurt, neuronal migration, myelination, etc.) can be rather 
diverse in different species.29 This makes it impossible – in principle – to develop 
animal models which reflect all or most aspects of human HIE and therefore requires 
researchers to take a holistic view of the strengths and limitations of various animal 
models. 
 Historically, the foundations of perinatal asphyxia research were laid down by 
the work of Myers and Brann on the rhesus monkey.30 Throughout the 1970s these 
studies employed both fetal and neonatal models of HIE with various methods of 
achieving hypoxia and/or ischemia and investigated cardiovascular as well as 
neurological outcomes in both acute and chronic settings.31-33 The major contributions 
of these studies to our understanding of perinatal HIE have been summarized by Raju as 
follows:34 (1) the immature brain has a greater degree of tolerance to an asphyxic insult 
than the mature brain; (2) in addition to a reduction in PaO2 (hypoxemia alone), 
ischemia is also required to cause measurable brain damage; (3) depending on the type 
of insult, two distinct patterns of neuropathological damage can be observed: acute 




oedema with neuronal necrosis in the cerebral hemispheres in case of prolonged partial 
asphyxia. Limitations of these primate models have also been pointed out, in particular 
that more severe maternal hypoxia is necessary to generate fetal CNS injury compared 
to humans, and also that the prevalent pattern of oedema with neuronal necrosis in the 
primate can rarely be seen in humans, while the human pathology of intra- and 
periventricular hemorrhage was scarcely observed in these animals. Additionally, by the 
1990s primate experiments have become increasingly difficult to conduct due to strict 
regulations and prohibitive costs. 
 The fetal or neonatal sheep has been one of the most important experimental 
large animal models in the investigations of cerebral blood flow (CBF) and brain 
metabolism during and after HIE. A large number of these studies were published in the 
1980s and they generally involved a Cesarean-section performed at varying periods of 
gestation and the instrumentation of the fetal lamb for later monitoring and 
manipulation.35-37 The uterus and the abdomen were closed and after 2-3 days of 
recovery either the mother or the fetus were subjected to hypoxia, hypercapnia, acidosis, 
anemia, polycythemia or other procedures. These studies played a major role in 
elucidating the specific effects of different components of asphyxia (hypoxia, acidosis, 
ischemia, etc) on CBF and brain energy metabolism, understanding the developmental 
aspects of CBF control and describing the extent and limitations of CBF autoregulation 
in the fetal lamb.34 The major limitations of these models include the fact that most of 
the studies focused on acute changes in CBF and brain metabolism and less so on the 
middle to long term outcomes of HIE, and also that cortical neuronal maturation before 
birth is much more rapid in the sheep than in the human. While a fetal lamb at 120 days 
(86%) of gestation can be considered similar to a term human infant regarding brain 
maturity, the neonatal lamb already possesses an adult pattern of cortical maturity.38 
Additionally, maintaining this model requires resources in laboratory space, personnel 
and funding which only a few centers can provide. 
 Parallel to the development of ovine preparations, the newborn piglet has also 
emerged in the 1980s as an affordable and ‘workable’ model in numerous laboratories.34 
These studies also focused primarily on the acute effects of HIE on CBF and brain 
metabolism, and thus confirmed and elaborated on many of the findings of lamb 




among researchers investigating diseases of the neonatal period.41 This is partially due 
to the emergence of magnetic resonance imaging and spectroscopy (MRI and MRS) as 
invaluable tools for the in vivo investigation of the brain as well as potential bridging 
biomarker modalities, which could possibly provide direct links between animal studies 
and the human clinical condition.42 The neonatal piglet is ideally suited for such 
investigations, owing to its similarity to human neonates in terms of brain development, 
as well as its optimal size for imaging.41 In the clinical translation of therapeutic 
hypothermia, piglet studies have been invaluable in providing guidelines about the 
timing and the optimal depth of hypothermia,43,44 a work which is still ongoing, as will 
be highlighted later on. 
With more than 1300 citations to the original 1981 paper, the single most widely 
used preclinical animal model of HIE is the Rice-Vannucci rodent model.24 In this 
preparation 7-days-old rat pups are subjected to permanent unilateral carotid artery 
ligation followed by a transient period of hypoxia. The authors of the original article 
cite Levine, who conducted experiments regarding the tolerance of adult rats to anoxia 
and ischemia.45 His 1960 paper reported that anoxia alone was unsuited for producing 
significant histological brain damage, as most of the animals either died or survived 
without lesions. Therefore, he introduced permanent unilateral carotid artery ligation to 
sensitize the forebrain to subsequent anoxia. Since these findings were in accordance 
with those of Myers et al. on rhesus monkeys,30 Vannucci and colleagues adopted this 
preparation to the immature rat, successfully producing significant unilateral brain 
injury without acute signs of neuromotor dysfunction.24 While numerous modifications 
to the original setup have been introduced since, including the occlusion of both carotid 
arteries46 or using different degrees of hypoxia for various durations, the core of this 
model has been instrumental in uncovering many pathophysiological features of HIE, 
including the depletion of high-energy phosphate metabolites as well as the role of 
excessive excitatory amino acid release in the development of brain injury.47  
The advantages of this preparation – its relative cost-efficiency and ease of use – 
are well reflected in its widespread adaptation and usage even today. However, if one 
considers the fact that more than 500 pharmacological agents were found to be 
neuroprotective in preclinical models of neonatal HIE in the past decades, while none of 




models becomes obvious.48 The reasons for this are probably several fold, but likely 
include: (1) the difficulty of determining the optimal age for comparison with the term 
human newborn; (2) the major anatomical differences between the rodent and the 
human brain (eg. archicortex volume, axonal myelination, grey/white matter ratio, 
developmental velocity); (3) the absence of particular patterns of injury in the rodent 
model, which are regularly seen in the human (eg. injury to the parasagittal cortex, 
subcortical white matter and brain stem); (4) the absence of systemic level multi-organ 
involvement, which is also commonly observed in severe cases of human HIE;49 (5) the 
invasive and permanent surgical ligation of one common carotid artery which has 
virtually no translational equivalent in human HIE.50 Additionally, a number of 
investigators have noted lately that while this preparation reliably produces some level 
of injury on most surviving animals, the variability of injury is still relatively large, 
which consequently requires a great number of animals to be sacrificed for each study.51 
While some researchers have tried to argue that this is in fact an advantage of the 
model, as such a variability is also seen in human infants with HIE,52 this difficulty of 
early patient stratification into meaningful prognostic groups is one of the reasons why 
human clinical trials in HIE require so prohibitively high number of subjects.48  
 
3.3 Neonatal HIE pathomechanisms 
 
Despite their limitations, animals models have enabled us to gain a mechanistic 
understanding of HIE pathology.30 An excellent paper by Michel J. Painter summarized 
the state-of-the-art of perinatal HIE research in 1995, which I will attempt to further 
expand using data from the last 20 years since that review was published.19 
 One of the earliest observations was that in addition to the direct detrimental 
effects of hypoxia and ischemia, neuronal death continued upon reperfusion.53 It was 
recognized early on that, in principle, this late neuronal death could be ameliorated via 
post-insult neuroprotective interventions and hence it has been the focus of numerous 
investigations. More recent studies showed that while a number of neurons indeed die 
during the primary phase of the injury, the hypoxia-induced impairment of cerebral 




(EAAs) typically recover, at least partially over approximately 30-60 minutes upon 
resuscitation.54 This period is usually followed by a ‘latent phase’, when the EEG is still 
suppressed, but high-energy phosphates have recovered to almost baseline levels.55 
During this phase cerebral metabolism is believed to be actively suppressed, since tissue 
oxygenation is increased while cerebral perfusion is reduced.56 In the case of moderate 
to severe HIE, this latent phase is generally followed by a ‘secondary energy failure’ 
(SEF), which is characterized by the accumulation of EAAs, cytotoxic edema, 
mitochondrial failure and spreading neuronal death. 57,58 More severe HIE appears to 
produce higher levels of neuronal death during the primary phase and also an earlier and 
more severe SEF with more extensive neuronal loss.57 Clinically, this is also the phase 
when stereotypic seizures usually occur.59 Finally, brain injury and repair is believed to 
continue for weeks or months after the SEF. This tertiary phase has recently become the 
focus of neuroprotection and –regeneration studies.60 Figure 1 summarizes the phases 
of cerebral injury in HIE as well as the dominant pathomechanisms, which will be 






Figure 1: Schematic diagram illustrating the different pathological phases of cerebral injury 
after cerebral HI, modified from Hassell et al, 2015.60 The primary phase (acute HI), latent 
phase, secondary energy failure phase and tertiary brain injury phase are shown. (A) Magnetic 
resonance spectra showing the biphasic pattern of NTP/EPP (high energy phosphates) decline 
and lactate/NAA (anaerobic metabolism) increase during primary and secondary phases 
following HI insult. Persisting brain alkalosis with high levels of lactate is shown in tertiary 
phase. (B) Amplitude-integrated EEG showing normal trace at baseline, flat tract following HI, 
burst-suppression pattern in latent phase, emergence of seizures in secondary phase and 
normalization with sleep–wake cycling in tertiary phase. (C) After HI, there is a period of 
hypoperfusion associated with hypometabolism during latent phase, followed by relative 
hyperperfusion in secondary phase. (D) Cellular energetics and mitochondrial function are 
reflected in the biphasic response shown on magnetic resonance spectroscopy (A), with a period 




recovery in tertiary phase. (E) The most important pathogenic changes are shown for each, 
including generation of toxic free radical species, accumulation of EAAs, cytotoxic edema, 
seizures and inflammation. Cell lysis occurs immediately following HI, while programmed cell 
death occurs in secondary phase; latent phase provides a therapeutic window. Persisting 
inflammation and epigenetic changes impede long-term repair. (F) Damage is maximal in the 
secondary phase, but persists into the tertiary phase as inflammation and gliosis evolve. HI, 
hypoxia-ischemia; EAAs, excitatory amino acids; EPP, exchangeable phosphate pool; NAA, N-
acetyl-aspartate; NO, nitric oxide; NTP, nucleoside triphosphate (this is mainly ATP); OFRs, 
oxygen free radicals;  
 
In most cases of HIE the primary pathological event is a disruption of maternal-
fetal gas-exchange, either due to acute or chronic causes (eg. placental abruption or 
chronic placental insufficiency, respectively).*61 This leads to decreased oxygen levels 
(hypoxemia) and accumulation of carbon-dioxide (hypercapnia) with associated 
respiratory acidosis in the blood. On the cellular level reduced oxygen availability 
impedes the operation of the mitochondrial respiratory chain, which in turn results in 
the accumulation of reduced electron carriers NADH and FADH and the interruption of 
oxidative phosphorylation. Without the mitochondrial electron transport chain the 
oxidation of NADH can only be accomplished via anaerobic respiration, during which 
pyruvate is converted to lactate by the enzyme lactate dehydrogenase, which also 
oxidizes equimolar amounts of NADH to NAD+. The process of anaerobic respiration, 
however, only produces 2 ATP molecules per glucose molecule, which is only about 5% 
of the amount produced via aerobic respiration (theoretically 38 ATP molecules per 
glucose molecule). This leads to the depletion of other intracellular energy stores, such 
as phosphocreatine, and eventually to the decline of intracellular ATP levels and the 
parallel accumulation of ADP and AMP.55 This decrease in the ATP / (ADP + AMP) 
ratio induces phosphofructokinase (PFK), which is the rate-limiting enzyme of 
glycolysis.19 The resulting overdrive of glycolysis will sharply increase the demand for 
glucose in order to at least partially compensate for the lack of high-energy phosphates. 
                                                 
* I will refer to J.J. Volpe’s Neurology of the Newborn textbook without repeated citations in the 





The initial increase of cerebral blood flow in response to hypoxia can, to some extent, 
satisfy this demand.19 However, a sustained lack of O2 will lead to a decline of heart 
muscle contractility and heart rate, and thus to a subsequent decrease in cardiac output, 
which will produce hypotension and cerebral ischemia.35 In turn, ischemia will again 
reduce the supply of oxygen as well as glucose to neurons, even further tipping the 
balance of energy metabolism. The accumulation of lactate and protons will create an 
intra- and extracellular acidosis, which will consume a large amount of plasma buffers, 
primarily HCO3
-. Henceforth, babies with severe HIE characteristically present with a 
combined respiratory and metabolic acidosis at birth, typically with low plasma pH, 
high pCO2, low standard HCO3
- and high lactate levels. 
 Intracellular acidosis, however, can also have protective effects during 
hypoxia/ischemia. PFK, the rate-limiting enzyme of glycolysis is highly sensitive to 
intracellular pH and acidosis strongly inhibits its function.62 Additionally, neuronal 
excitability is also highly dependent on intra- and extracellular pH via a variety of 
mechanisms, the sum effect of which can be strikingly different in various neuronal 
populations.63 Acidification can increase excitability in certain neuronal types, like 
chemosensitive neurons in the brain stem, while other neuronal types, such as 
hippocampal pyramidal neurons are strongly inhibited by acidosis. As hippocampal 
neurons are among the most sensitive to hypoxic injury, this protective effect of acidosis 
can have an important role in HIE pathophysiology.64 
 While the failure of cellular energy metabolism is one of the most important and 
well-studied phenomena during hypoxia-ischemia, other pathomechanisms also play a 
significant role. One such process is the generation of free radicals. As discussed above, 
the shortage of oxygen supply halts oxidative phosphorylation and forces the cell 
towards anaerobic respiration. However, the slowing down of the mitochondrial ATP 
synthesis also implies that the reduction of O2 will be only partial and non-enzymatic 
free radical generation will be stimulated.65 Additionally, the hypoxia-induced 
accumulation of arachidonic acid and the calcium-induced activation of phospholipase 
A2 will result in the activation of prostaglandin synthesis, which also generates free 
radicals.65 Finally, the failure of cellular energy metabolism will lead to the 
accumulation of breakdown products from high-energy phosphate compounds. This 




Under physiologic conditions, hypoxanthine is converted to xanthine and further on to 
uric acid by xanthine-dehydrogenase which utilizes NAD+ as a cofactor. During 
hypoxia, however, xanthine-dehydrogenase is converted to xanthine-oxidase via 
calcium-induced proteolysis and this enzyme utilizes molecular O2 instead of NAD+ as 
a cofactor, thus generating superoxide anions.65 In addition to oxygen free radicals, 
there is also compelling evidence to suggest the detrimental role of nitrogen free 
radicals (RNS) in HIE pathology, primarily via the generation of nitric oxide (NO•) by 
neuronal nitric oxide synthase (nNOS).54  The reaction of NO• with superoxide in the 
cytosol and mitochondria can lead to the generation of highly reactive peroxynitrite and 
other RNS compounds.67 Even though free radical generation is induced during and 
following hypoxia-ischemia, its scavenging enzymes such as superoxide dismutase and 
glutathione peroxidase are insufficiently expressed during the perinatal period.68 The net 
effect is an increased free radical load, which can exert a variety of detrimental effects, 
from lipid peroxidation to DNA/RNA-fragmentation and thus contribute to HIE 
neuropathology.54 Accordingly, preclinical experiments demonstrated the benefits of 
preventive maternal administration of allopurinol, an inhibitor of xanthine oxidase as a 
potentially neuroprotective intervention.69  
 As described previously, cellular energy metabolism initially attempts to 
compensate for the lack of O2 during hypoxia-ischemia via increasing the rate of 
anaerobic respiration, but this mechanism rapidly becomes insufficient and intracellular 
high energy phosphate levels begin to fall.19 Under physiological conditions the largest 
consumers of ATP are protein synthesis and the Na+/K+ pump. While non-essential 
protein synthesis is quickly blocked upon hypoxia,70 the function of the Na+/K+ pump is 
essential even under such conditions, since it constantly maintains the high potassium 
and low sodium concentrations intracellularly. The transmembrane Na+ gradient is the 
primary driver of a number of other ionic processes, contributing to the maintenances of 
pH- and calcium-homeostasis. The K+ gradient is essential for the repolarization of 
membrane potential in excitable cells. During uncompensated hypoxia, the lack of ATP 
will compromise the operation of the Na+/K+ pump and lead to membrane 
depolarization via Na+ and Ca2+ entry into the cells.54 One immediate effect of the influx 
of ions is the concomitant entry of water and subsequent cell swelling.61 While this so 




upon reperfusion these swollen neurons recover, at least temporarily.54 After the latent 
phase, however, more severe cytotoxic edema will develop, which can be measured in 
vivo via diffusion-weighted magnetic resonance imaging, which is a sensitive marker of 
the extent of hypoxic-ischemic injury.71 
 Failure of the Na+/K+ pump and subsequent membrane depolarization will lead 
to the release of excitatory neurotransmitters to the synaptic cleft, primarily glutamate.54 
Excessive release of EAAs will trigger the activation of NMDA, AMPA and other 
receptor-channels on post-synaptic neurons, which will cause disproportionate calcium 
and further sodium entry into these cells.72 This intracellular calcium surge will activate 
a number of downstream pathways, including the over-activation of enzymes such as 
calpains and other proteases, protein kinases, calcineurin, endonucleases and nitric 
oxide synthase, which in turn can further increase free radical generation.72 In this 
context, EAAs and intracellular calcium appear to be important mediators of cellular 
injury in HIE.54 
  As shown in Figure 1, a number of pathological features of hypoxia-ischemia 
recover to almost baseline levels within 30-60 minutes after resuscitation.60 Cytotoxic 
edema subsides, EEAs are removed from the synaptic cleft and intracellular high energy 
metabolites recover.  This so-called latent phase usually lasts between 6 and 24 hours 
after recovery and is considered the primary therapeutic time window, when 
intervention could prevent or ameliorate subsequent injury.60 Some studies suggest that 
during this phase, cerebral metabolism might be actively suppressed by endogenous 
protective mechanisms, as indicated by the simultaneously present decreased cerebral 
perfusion and increased tissue oxygenation, consistent with decreased oxygen 
consumption.56 This suggested controlled hypometabolism has important implication 
for both clinical practice and preclinical research, as will be discussed later. 
 Approximately 6-24 h after the initial insult, a secondary energy failure has been 
described both in preclinical57 and clinical studies73 using phosphorus-31 MRS (31P-
MRS). The 31P-MRS spectra consists of phosphorus-containing metabolites, including 
phosphocreatine (PCr), inorganic phosphate (Pi) and nucleoside triphosphates (NTP). 
There are three NTP peaks in the 31P spectra, α-, β-, and γ-NTP, corresponding to the 
three phosphate groups on NTP molecules (primarily ATP, but also including guanosine 




metabolites (PCr and NTP) fall and Pi increases. Additionally, persistently high levels of 
intracerebral lactate75 and an alkalotic shift in intracellular pH can also be observed,76 
which are associated with later neurodevelopmental impairments. This secondary phase 
is also marked by secondary cytotoxic edema, accumulation cytokines and excitotoxins, 
mitochondrial failure, and clinically the onset of seizures (see Figure 1).54 A tertiary 
cerebral hyperperfusion takes the place of the previous, actively suppressed cerebral 
metabolic state.77 These various processes likely contribute to the spreading neuronal 
death continuing for days or even weeks after the initial insult.60 
 The precise pathomechanisms involved in this secondary energy failure are not 
fully understood yet, but they likely involve excessive calcium influx, inflammatory 
mediators, and activation of pro- and anti-apoptotic proteins as well.54 Mitochondrial 
failure appears to be a central feature of the SEF, upon which a number of these 
processes converge. Figure 2 summarizes some of these processes.54 
 
 
Figure 2: Intracellular mechanisms associated with the permeabilization of the mitochondrial 
membrane leading to apoptosis, modified from Wassink et al.54 Upstream triggers such as 
inflammatory mediators and withdrawal of trophic support can activate the extrinsic pathway of 
apoptosis, while calcium accumulation and ROS can induce the intrinsic pathway. Some 




AIF, apoptosis inducing factor; Apaf-1, apoptotic protease-activating factor−1; ATP, adenosine 
triphosphate; BAK, Bcl2-antagonist/killer1; BAX, Bcl2-associated × protein; Bcl2, B-cell 
lymphoma 2 protein family; Bcl-XL, B-cell lymphoma-extra-large; BID, BH3 interacting-
domain death agonist; Diablo, direct inhibitor of apoptosis binding protein with low Pi; P53, 
p53 tumor suppressor protein; Smac, Second mitochondria-derived activator of caspase; tBID, 
truncated BH3 interacting-domain death agonist; TNF, tumor necrosis factor receptor; TRAIL, 
TNF-related apoptosis-inducing ligand receptor 
 
A central feature of secondary energy failure appears to be a cellular 
accumulation of calcium due to excessive glutamatergic activation. This calcium build-
up can be buffered by the mitochondria up to a certain level.78 Above this, however, it 
can inhibit the function of the electron transport chain, uncouple oxidative 
phosphorylation and lead to a permeabilization of the mithochondrial membrane, which 
results in the activation of the intrinsic apoptotic pathway.72 This process occurs via the 
translocation of the cytosolic pro-apoptotic Bax to the mitochondrial membrane, where 
it forms transition pores together with Bak and Bid, all members of the apoptotic Bcl-2 
family.79 This allows the leakage of pro-apoptotic proteins, such as the second 
mitochondria-derived activator of caspase (Smac), the direct inhibitor of apoptosis 
binding protein with low Pi (Diablo) and apoptosis inducing factor (AIF), as well as 
cytochrome c to the cytosol.79 While the loss of cytochrome c oxidase itself could 
impair energy metabolism, these processes also trigger further downstream effector 
mechanisms. These include the activation of the initiator caspase 9 and the subsequent 
formation of the apoptosome, which in turn will activate effector caspase 3 and 
ultimately lead to DNA fragmentation, membrane blobbing and apoptotic cell death.80 
There is a good amount of evidence showing that apoptotic cell death is indeed an 
important contributor to HIE neuropathology.81  Additionally, a number of other 
pathological processes during this secondary energy failure stage can result in, or 
contribute to apoptotic neuronal death, including the loss of trophic support by 
astrocytic growth factors,82 inflammatory mediators,83 and the induction of the extrinsic 
apoptotic pathway via the activation of death receptors Fas and TRAIL.84 Recent 
consensus suggests, however, that the classification of injury as apoptotic vs. necrotic 
might be inadequate and instead there is probably a continuum of phenotypes between 




 There is now accumulating evidence to show that following the SEF, a tertiary 
phase of active pathological processes takes place, which continues for weeks, months, 
even years.86 This is consistent with the observation that high levels of cerebral lactate 
and brain alkalosis can persist for over a year in babies with severe neurodevelopmental 
impairment.75 Pathomechanisms during this phase are yet poorly understood, but likely 
involve the proliferation of astrocytes and the formation of glial scar, persistent 
inflammatory activation and epigenetic changes. 
 
3.4 Experimental neuroprotective interventions 
 
Owing to the growing understanding of the pathomechanisms involved in neonatal HIE, 
there has been a number of experimental therapies designed to prevent or ameliorate its 
neurodevelopmental sequelae. Hypothermia, as the only therapeutic intervention to date 
with clinically proven safety and efficacy, will be described comprehensively in the 
following section. Before that, a brief overview is provided regarding the experimental 
therapies investigated in recent years. 
 One of the most intensively researched interventions has been the application of 
inhaled xenon.69 Xenon is a non-competitive NMDA-antagonist with a wide range of 
effects on downstream intracellular pathways, ultimately providing a strong anti-
apoptotic effect.69 Several groups have demonstrated its neuroprotective effects in 
preclinical models.87-89 A recent clinical trial, however, failed to show the additional 
benefit of 30% xenon administration in addition to hypothermia.90 There are two other 
ongoing trials investigating the benefits of different xenon administration protocols 
(clinicaltrials.gov, NCT01545271 and NCT02071394). 
 As described before, the inhibition of xanthine-oxidase during hypoxia has been 
suggested as a potential way to decrease oxidative damage during HIE. Preclinical 
experiments demonstrated the benefits of preventive maternal allopurinol 
administration, an inhibitor of xanthine oxidase.69 Recent clinical trials, however, could 
not provide sufficient support for these claims.91 
 Another suggested experimental intervention has been the administration of 




melatonin influences a wide range of physiological functions, including growth and 
development, reproduction and the immune response.60 Its neuroprotective effects have 
been demonstrated in a number of preclinical models92,93 and the mechanisms likely 
involve anti-oxidant, anti-apoptotic and anti-inflammatory effects.60 Clinical trials are 
now underway to provide information about optimal dosing regimens and potential 
neuroprotective effects (clinicaltrials.gov, NCT02621944). 
 Finally, erythropoietin (EPO) has also been suggested as a potential 
neuroprotective agent after neonatal HIE.60 In addition to its role as a hematopoietic 
growth factor, EPO is known to be highly important for normal brain development in 
utero and appears to be an important mediator of the brain’s endogenous protective 
mechanisms via anti-apoptotic, anti-inflammatory and anti-oxidative effects.60 A 
number of clinical trials involving various protocols of EPO administration are currently 
underway.94 
Until today, however, the only intervention proven to be safe and effective was 
therapeutic hypothermia. 
 
3.5 Therapeutic hypothermia 
 
It is probably no overstatement that therapeutic hypothermia has been the most 
important recent development in the care of infants with HIE. The concept itself, 
however, is probably almost as old as medicine itself. The first description of intentional 
cooling to reduce neurological injury comes from Hippocrates, from approx. 400 BC, 
who suggested packing wounded soldiers in snow and ice.95 The first record of 
therapeutic hypothermia in newborns dates back to the 17th century, when Sir John 
Floyer described the immersion of a still-born infant into ice water in order to stimulate 
the onset of respiration:96 
 
“Sarah Parks . . . gave still-birth to a baby boy . . . A young doctor assisting the Parks’ 
regular physician begged for an opportunity to experiment with an idea he had to rouse 
the lifeless infant. A tub of ice was ordered and the young doctor plunged the baby into 




prodded him to life.” 
Sir John Floyer, 1697 
 
The first scientific attempt to use hypothermia in the resuscitation of asphyxiated 
newborns was made by James Miller from New Orleans and Björn Westin from 
Stockholm in the 1950s. After conducting a series of animal experiments to demonstrate 
the beneficial effect of cooling on survival from asphyxia,97 they organized the first 
pilot study of therapeutic hypothermia. Ten severely depressed newborns who did not 
respond to resuscitation were immersed in a cold water bath until spontaneous 
respiration commenced or their rectal temperature decreased to 27 ˚C.98,99 Four of these 
infants also received oxygenated blood transfusions. After resuscitation, the infants 
were dried and allowed to rewarm spontaneously. One of the 10 infants died due to 
respiratory distress syndrome, but the other nine survived and did not show neurological 
impairment in a 10-year follow-up study, despite the fact that their periods of apnea 
ranged from 8 to 79 minutes.100 After their initial success Miller and Westin proceeded 
to conduct a larger study of cooling on 65 infants unresponsive to standard resuscitation, 
52 of whom survived, which was an outstanding result at the time.97 Small scale clinical 
trials were also conducted elsewhere in the 1960s, from California to Switzerland and 
Finland.101-104  
 Despite these hugely promising results and the championing of cooling for 
severely depressed newborns by Westin and Miller, which they continued in the 1970s, 
the general international medical community did not adopt the concept of therapeutic 
hypothermia. One of the primary reasons for this was likely the publication of another 
scientific paper almost simultaneously with Miller and Westin’s first study. In 1958 
Silverman and colleagues reported a study of 182 premature infants, who were kept in 
normothermic (31.9 ˚C) or hypothermic (28.9 ˚C) incubators for the first 5 days of 
life.105 The overall survival was 68% in the hypothermic group versus 83% in the 
normothermic group. Despite the fact that later re-analysis showed that most of the 
mortality in the hypothermic group occurred in infants <1000g and that there was a 
sampling bias between the two groups, which together could explain at least some of the 
results, this study propelled a large amount of research into neonatal thermoregulation 




temperatures of newborns.96 Even though the Silverman study was conducted on 
preterm babies, the extrapolation about the dangers of hypothermia to term newborns 
was generally accepted by clinicians. 
 It was only in the 1990s that neonatologists started to question the dogma 
concerning the dangers of hypothermia in the neonatal period. The causal relationship 
between postnatal hypothermia and mortality in preterm infants, suggested by the 
Silverman paper was called into question by a more detailed study by Hazan and 
colleagues in 1991.106  By the late 1990s a sufficient amount of data from animal studies 
have emerged which all supported the potentially beneficial effects of mild to moderate 
hypothermia after resuscitation from hypoxia-ischemia (HI).18  
 The first pilot safety study of selective head cooling in asphyxiated newborns 
was published in 1998 by Gunn and colleagues.107 Whole-body cooling was also 
successfully tested in a clinical pilot safety study two years later.108 The first 
randomized multicenter study evaluating the efficiency of selective head cooling for 
neonatal HIE was the CoolCap trial, the results of which were published in 2005.109 
Even though that study only found significant improvement in neurological outcome in 
infants with moderate HIE, two other studies using whole-body hypothermia were 
published the same year, both of which found significant improvement in the risk of 
death or disability in infants with both moderate and severe HIE.110,111 The largest trial 
of whole-body hypothermia published interim results in 2008 7 and the final outcomes 
in 2009.11 After enrolling 325 infants, the TOBY study concluded that cooling to 33.5 C 
for 72 hours, if started within the first 6 hours of life, leads to improved neurological 
outcome in survivors, even though it could not identify significant reduction in the risk 
for death or severe disability which was the study’s primary outcome. A subsequent 
meta-analysis of hypothermia trials, encompassing 1320 infants was necessary to 
demonstrate with adequate statistical power that moderate hypothermia consistently 
improves both survival and neurological outcome at 18 months of age in infants with 
moderate HIE, but this effect was still not significant for infants with severe HIE.10 
Only in 2012 and 2013 could two revised meta-analyses conclude that infants with 
severe HIE also benefit from therapeutic hypothermia and unequivocally put 
hypothermia in the standard protocol of care for infants with HIE.112,113 Still, concerns 




three major clinical trials has already been published and while all suggest benefits of 
hypothermia in this age group as well, the studies were not powered to draw such 
conclusions with statistical significance.12,114,115 Undoubtedly, an ongoing data 
collection from many centers employing similar standard protocol for cooling is 
necessary to further understand the benefits and limitations of therapeutic hypothermia. 
 
3.6 Mechanisms of action in therapeutic hypothermia 
 
The mechanisms of hypothermic neuroprotection are several-fold. Hypothermia reduces 
cerebral metabolism by approximately 5% for every 1 ˚C decrease in body 
temperature.116 Hypothermia during HI delays the onset of anoxic depolarization, 
reduces the amount of EEAs and potentially suppresses ROS and RNS formation.54 If 
hypothermia is initiated upon reperfusion/resuscitation, it appears to accelerate the 
normalization of extracellular EEAs, ROS sequestration and recovery of high-energy 
phosphates.117  
 Clinically, however, hypothermia treatment can be started realistically only a 
few hours after birth.118 The effect of hypothermia on secondary (and tertiary) injury is 
thus highly important. Microarray studies suggest that hypothermia can suppress a large 
number of gene responses to ischemia, many of which are involved in calcium 
homeostasis, cellular and synaptic integrity, inflammation and apoptosis.119 As 
described before, pro-apoptotic processes are incredibly complex and involve a large 
number of redundancies, therefore it is difficult to conduct and interpret studies 
including the manipulation of individual mediators. However, the caspase-dependent 
activation of apoptosis does generally converge on caspase-3 as a final executioner, 
which makes it a reasonably good indicator of upstream processes. Accordingly, 
delayed hypothermia was found to decrease caspase-3 activation after HI in the near-
term fetal sheep.120 This finding was confirmed in both rodent121 and in piglet 
models.122 There is also evidence from adult animal studies that post-reperfusion 
hypothermia can suppress the mitochondrial permeability transition and prevent the 




 The inflammatory cascade induced by HI can cause injury via the activation of 
apoptotic cell death, or via direct damage from inflammatory cells, such as microglia or 
leukocytes.124 This inflammatory signaling appears to be interrupted by hypothermia at 
a number of sites, as cooling was found to decrease the levels of various pro-
inflammatory cytokines as well as to directly suppress microglial activation.125  
 The fact that therapeutic hypothermia needs to be maintained for at least 48 
hours in order to be effective suggests that a continued suppression of programmed cell 
death and inflammation is necessary until normal homeostasis can return.126 
Additionally, hypothermia results in suppressed cerebral hyperperfusion, edema 
formation and seizure activity that could all indicate or contribute to neuroprotection.77 
As these effects on a wide range of deleterious processes are combined, it is not hard to 
appreciate the level of protection offered by hypothermia. Hence it is reasonable to ask 
what may be the optimal setting for administering hypothermia in order to achieve 
maximal protection. 
 
3.7 Application of therapeutic hypothermia 
 
One important aspect of therapeutic hypothermia is the method of administration. One 
of the large clinical trials, the CoolCap study utilized selective head cooling,109 which 
was previously successfully used in large animal models as well.59 This method can 
produce selective head cooling with only mild systemic hypothermia. However, as 
discussed before, the CoolCap trial could only identify potential benefit of hypothermia 
in a selected subgroup of infants with HIE. Insight into the potential reasons for this was 
provided by piglet studies showing that different CNS structures have different optimum 
temperatures for protection.127 In these experiments optimal protection for cortical 
neurons was achieved at 35 ˚C, while deep gray matter structures required 33.5 ˚C for 
maximal neuronal sparing. These results, together with previous studies showing that it 
is challenging to achieve adequate cooling of deep brain structures by surface cooling 





 Another important aspect of the administration of therapeutic hypothermia is the 
initiation and the length of cooling. Inclusion criteria of the large multi-center trials 
involved the initiation of cooling within 6 hours after birth.7 This time was chosen as a 
practical compromise between the clinical reality of birth asphyxia (many such children 
are born out-of-hospital and require transport to a tertiary center) and the results of 
animal studies, which showed that delayed hypothermia can be neuroprotective, but 
only if started before the occurrence of seizures, i.e. during the latent phase.130 The 
length of cooling was set to 72 hours in order to achieve maximum protection, as 
preclinical studies indicated an inverse relationship between the depth and length of 
cooling necessary to achieve neuroprotection.131 72 hours of cooling was found to be 
safe and effective in translational large animal models of HIE.59 The potential benefits 
of stretching both ends of the cooling period are now being evaluated.  Earlier start of 
cooling, for example during neonatal transport has been studied at a number of centers. 
It appears to be feasible and safe using servo-controlled cooling devices132 and while 
definitive results regarding neurological outcomes are still lacking, preliminary data 
suggest improved neuroprotection with earlier initiation of cooling.133 On the other 
hand, the potential prolongation of cooling was evaluated in two recent clinical trials. 
One of these trials was halted interim due to the lack of observed benefit in survival 
from either 120 hours vs 72 hours of cooling, 32 ˚C vs 33.5 ˚C target temperature, or 
both.134 The other trial examining the effect of late, prolonged cooling initiated between 
6-24 hours after birth and maintained for 96 hours has not published its results yet.135  
 Although these recent results show a lack of benefit with cooling to 32 ˚C 
instead of 33.5 ˚C, animal studies have indicated that deeper cooling might offer better 
protection.136 However, it appears that there is be a clear trade-off between the depth of 
cooling and the systemic-side effects of hypothermia. For example, deep hypothermia 
(15 ˚C) after cardiac arrest in the adult dog was found to be detrimental,137 while 
moderate hypothermia (28-32 ˚C) offered no protection138 and only mild hypothermia 
(34-36 ˚C) resulted in consistently improved neurological outcomes.139 The question of 
whether deeper hypothermia might offer better protection is especially important now 
that a large number of physicians start to adopt therapeutic hypothermia as standard of 




available. Therefore, it is essential to determine the optimal cooling temperature for 
infants with HIE. 
 
3.8 Hypothermia as an endogenous protective mechanism 
 
Even though recent successes with ‘artificial’ therapeutic hypothermia has raised a large 
amount of interest in the past decade, the first observations about ‘endogenous’ 
hypothermia as a response to hypoxia were made more than 50 years ago. In 1955 
Cross, Tizard and Trythall observed that infants breathing 15% O2 had reduced 
metabolic rate and heat production.140 While their experiments could not show 
decreases in rectal temperature during the brief period of 15% hypoxia, another report 
showed that maintaining this O2 level for a week resulted in a significant decrease in 
temperature as well.141 Instead of this approach of induced hypoxia, Burnard and Cross 
decided to study infants after birth asphyxia, as natural model of hypoxia and found that 
asphyxic babies had significantly reduced body temperatures (approx. 35 ˚C) for several 
hours after birth (Figure 3A).142 This finding has also been confirmed more recently in 
a trial of therapeutic hypothermia under low-resource settings in a developing country, 
where this ‘natural cooling’ was present in the normothermic asphyxia group for an 
average of 15 hours, despite attempts of active rewarming (Figure 3B).143  
 
 
Figure 3: Endogenous hypothermia in neonates after birth asphyxia. (A) shows the seminal 




line) had significantly lower rectal temperatures than healthy newborns (solid line) for several 
hours after birth.142 Note the lack of quick rewarming even in healthy newborns. Data is 
displayed as mean and 95% confidence intervals. (B) is adopted from a recent clinical trial of 
hypothermia in low-resource settings, which shows that the normothermic control asphyxia 
group (blue line) remained at sub-normal temperatures for several hours after resuscitation, 
despite efforts of rewarming.143 Data is displayed as mean ± SEM. The dashed red line shows 37 
˚C rectal temperature on both graphs. Adopted from Burnard and Cross, 1958 142 and Robertson 
et al, 2008 143.  
 
 Following the initial human observations in the 1950s, hypoxic hypometabolism 
was also studied in newborn lambs, puppies, kittens and rats.144,145 It appeared that since 
many of these species are born at a lower degree of maturity, endogenous protection 
against accidental and transient hypoxia might be evolutionarily beneficial. In the 
pursuing decades experimental research about the mechanism and role of hypoxic 
hypometabolism have expanded greatly and this body of knowledge have been the 
subject of a number of excellent reviews.146-150 
 Neonatal responses to hypoxia, including hypometabolism and a biphasic 
ventilatory response have often been considered as peculiarities by physicians, 
comparing them to adult physiology. It is important to note, however, that these 
processes have very similar analogues in lower species, which possess a greater 
tolerance to hypoxia than adult mammals.147 Studies confirmed that the decrease in 
metabolism in response to hypoxia is not due to the reduced oxygen availability, since 
lactate production was not increased, therefore anaerobic metabolism did not have to 
compensate for the reduced O2-supply.
146 Another potential explanation of hypoxic 
hypometabolism might be the effect of decreasing temperature itself, which is known to 
slow down metabolism and result in a decreased metabolic rate. However, the drop in 
metabolic rate actually precedes the decrease in temperature, so hypothermia itself 
cannot cause the hypometabolism.148 Additionally, it was found that the magnitude of 
hypometabolic response to hypoxia is primarily determined by the level of baseline 
metabolic rate, which in turn depends on several factors, including body size, age and 
ambient temperature.151 Since newborns have limited thermal insulation, they require a 




Consequently, this also allows for a potentially higher magnitude of hypometabolic 
response compared to adults.151 
In addition to the decreased metabolic rate and O2 consumption, a decrease in 
thermogenesis was also found to be an important contributor to the hypoxic response.152 
In newborns thermogenesis is primarily non-shivering and is mediated via brown 
adipose tissue (BAT), therefore this appears to be the center of this effect.146 
Hypometabolism and decreased thermogenesis by BAT can both contribute to 
endogenous hypothermia. A normal reaction to decreased body temperature in newborn 
animals could involve huddling by the pups, but this behavioral response is also 
suppressed during hypoxia.153 
In summary, the controlled decrease in O2-consumption (hypometabolism) and 
the reduction of BAT- and behavioral thermogenesis together suggest a central 
neurohormonal regulatory mechanism closely coordinating these responses.148 This 
theory is confirmed by the fact that denervation of peripheral chemoreceptors does not 
decrease the hypometabolism response.152 The regulatory mechanisms responsible for 
this coordination are still unknown, but the decreased concentration of O2 not as a 
substrate, but as a messenger has been discussed repeatedly.148 Another suggested 
mediator might be arginine-vasopressin (AVP, previously called anti-diuretic hormone 
or ADH),154 an important stress-hormone in the perinatal period, the level of which is 
greatly increased in asphyxic babies.155 
While the exact mechanism of the controlled decrease in metabolism and body 
temperature is not clear, their synergistic role in protection from hypoxia is well-
established, partially due to the mechanisms discussed in the previous parts. 
Accordingly, it is important to note that in a hypoxic newborn, artificial increase of 
body temperature (as standard postnatal care) results in tachypnea and a drop in 
systemic vascular resistance which would indicate the newborn’s attempts to dissipate 
heat.156 This suggests that the ‘normothermic’ temperature of an asphyxic newborn 
might be lower than that of a healthy neonate. 
All this highlights the importance of taking a more physiological and 
evolutionary point of view by clinicians and taking into consideration the lessons 
learned from comparative physiology instead of solely relying on, and striving to 




incorrectly extrapolated from adult standards. A similar lesson could be drawn from the 
slow acceptance of resuscitation with room air instead of 100% O2, when the former 
practice is supported by a large body of physiological and experimental data, while the 
latter was a direct adaption of adult resuscitation guidelines.157 Instead of considering 
hypothermia as an exogenous neuroprotective therapy, it might be more relevant to 
think of it as a measure supporting and securing an endogenous protective mechanism 
in order to maximize its benefits. This has over-arching implications for neonatologists 
working directly with infants just after suffering a period of asphyxia. 
 
3.9 Endogenous hypothermia in preclinical research 
 
As we have seen, most of our understanding regarding hypoxic hypometabolism and the 
resulting hypothermia comes from well-designed animal physiology studies from a 
number of species. Preclinical drug research, however, has mostly ignored this 
phenomenon. One example of this are the previous and highly successful animal studies 
using the NMDA-antagonist MK-801, which have failed to consider endogenous 
hypothermia resulting from the administration of the drug and thus included a 
significant confounder.46,158 There has been more than 500 neuroprotective agents which 
showed efficacy in preclinical trials but failed in the clinical translation process.48 
Therefore we should consider all possible sources of variation or noise potentially 
contributing to this unfortunate phenomenon. One such confounder is endogenous 
hypothermia. 
 As we have seen previously, hypoxic hypometabolism is a highly conserved 
mechanism, even though its magnitude depends on a number of factors, including 
postnatal age, weight and ambient temperature.148 Thus, in order to exclude or control 
for the effect of hypoxic hypometabolism, one has to closely monitor both ambient 
temperature and rectal temperature in the experimental animals. A strict control of rectal 
temperature is generally part of protocols with large animal models, as these systems 
aim to closely mirror the clinical situation.159 On the other hand, monitoring of rectal 
temperature in neonatal rodent models is more cumbersome, as it inevitably leads to 




Some groups have adopted a sentinel monitoring method, where only one animal from 
the experimental group is monitored.160 Others are attempting to assess thermogenesis 
directly by measuring skin temperature from above the inter-scapular BAT.161 Without 
direct measurement of core temperature or BAT thermogenesis, it becomes very 
difficult to closely monitor and control the thermal homeostasis of neonatal rodents, 
especially during hypoxia. Ambient temperature and baseline metabolic rate are major 
determinants of the magnitude of hypoxic hypometabolism.148 Using higher ambient 
temperatures can minimize the baseline metabolic rate and thus could also minimize the 
magnitude of hypometabolic response.161 Ambient temperature monitoring, however, 
can be also challenging, as the type, response-rate and placement of the sensors likely 
varies greatly between laboratories.  
 Reviewing a set of publications citing the original Rice-Vannucci paper 24 one 
finds that some groups appear to use a strict control of rectal temperature,162 while 
others only monitor ambient temperature to some degree.163-165 This raises the 
possibility that imprecise control of experimental temperatures, without specific 
attention to the effects of hypoxic hypometabolism, could conceivably influence 





4.  OBJECTIVES 
 
The objectives of this thesis can be summarized as follows: 
 
1. To investigate the effects of cooling to different target temperatures in a 
preclinical piglet model of HIE. In particular, to examine the safety and 
efficacy of deep hypothermia (30 ˚C) utilizing clinical outcome markers and 
neuro-pathological indicators. 
2. To examine the confounding effect of inadvertent hypothermia during and 
after hypoxia in a rodent model of HIE. 






5.  METHODS 
 
5.1 Piglet experiments 
 
Detailed descriptions of methods and procedures can be found in the corresponding 
publications.122,159,167 
 
5.1.1 Animal preparations 
 
All experimentation was conducted under UK Home Office Guidelines (Animals 
(Scientific Procedures) Act 1986) and approved by the institutional animal care and use 
committee of the University College London Biological Services and Institute of 
Neurology. Twenty-eight large white male piglets, less than <24 h old were anesthetized 
and surgically prepared as described previously.57 Briefly, the animals were sedated by 
an intramuscular injection of midazolam (0.2 mg/kg) and arterial O2 saturation 
monitoring was started (Nonin Medical, Plymouth, MA). Isoflurane anesthesia (4% 
vol/vol) was established via a facemask to facilitate tracheostomy and intubation. 
Isoflurane was maintained at 3% during surgery and at 2% afterwards. Piglets were 
mechanically ventilated so as to maintain temperature corrected arterial pressures of 
PaO2 (8-13 kPa or 60-100 Hgmm) and PaCO2 (4.5-6.5 kPa or 33-48 Hgmm). An 
umbilical venous catheter was introduced to administer maintenance fluids (10% 
dextrose, 60 ml/kg/d), fentanyl (3–6 μg/kg/h), and antibiotics (benzylpenicillin 50 
mg/kg and gentamicin 2.5 mg/kg, every 12 h). An umbilical arterial catheter was also 
inserted for continuous monitoring of heart rate (HR) and mean arterial blood pressure 
(MABP) and for 6-h blood sampling to measure PaO2, PaCO2, pH, electrolytes, glucose, 
and lactate (Abbot Laboratories, UK). Bolus infusions of colloid (Gelofusin; B Braun 
Medical, Emmenbrucke, Switzerland) and inotropes (dopamine and dobutamine 5–20 
μg/kg/min, noradrenaline 0.1–5 μg/kg/min) were used to maintain MABP above 40 mm 
Hg. Hyperglycemia of more than 10 mmol/l was treated by changing from 10% to 5% 




saline infusion. Severe metabolic acidosis (base excess > −10 mmol/l) was corrected 
with sodium bicarbonate (8.4% wt/vol). All animals received continuous physiological 
monitoring (SA instruments, New York), and intensive life support throughout 
experimentation. Arterial lines were maintained by infusing 0.9% saline solution 
(Baxter, 1 ml/h) with heparin sodium (1 IU/ml) to prevent line blockage. Both common 
carotid arteries were surgically isolated at the level of the fourth cervical vertebra and 
encircled by remotely inflatable vascular occluders (OC2A; In Vivo Metric, Healdsburg, 
CA). After surgery, piglets were positioned prone in a plastic pod with their heads 
immobilized.  
 
5.1.2 Induction of cerebral hypoxia-ischemia 
 
A magnetic resonance spectroscopy surface coil was secured to the cranium, and the 
animal was positioned in a 9.4 Tesla Varian magnetic resonance spectrometer. While in 
the spectrometer, transient HI was induced by inflating the vascular occluders and 
reducing fractional inspired oxygen (FiO2) to 12% (vol/vol). During HI, cerebral 
energetics were monitored every 2 min by phosphorus (31P) MRS, and the β-nucleotide 
triphosphate (β-NTP, consisting mainly of adenosine triphosphate) peak height was 
automatically measured. When β-NTP had fallen to 40% of baseline levels, FiO2 was 
adjusted in order to stabilize β-NTP at that level for 12.5 min, after which the occluders 
were deflated and FiO2 normalized. 
31P spectra were acquired for a further 1 h to 
monitor recovery from HI. The time integral of the decrement of β-NTP/EPP (EPP = 
exchangeable phosphate pool = inorganic phosphate + phosphocreatine + high energy 
phosphates) during HI and the first 1 h of resuscitation quantified the acute energy 
depletion (AED) as described previously.57 
 
5.1.3 Experimental groups 
 
Following HI and resuscitation piglets were randomized into four groups: (I) 
normothermia (rectal temperature (Trec) 38.5 °C throughout), or whole-body cooling 
between 2–26 h after the insult to (II) Trec 35 °C, (III) Trec 33.5 °C, or (IV) Trec 30 °C 




heated water mattress above and below the animal; hypothermic piglets were cooled by 
reducing the water mattress temperature to their target Trec over 90 min, starting 2 h 
after HI. At 26 h after HI, cooled piglets were rewarmed to normothermia with a 
maximum speed of 0.5 °C/h using the water mattress. Forty-eight hours following HI, 
piglets were euthanized with pentobarbitol, the brain was fixed with cold 4% 
paraformaldehyde (PFA) via cardiac perfusion and removed along with major organs 
and processed for histology and immunohistochemistry. 
 
5.1.4 Serum cortisol & troponin measurements, pathological examinations 
 
The measurement of serum cortisol and troponin levels from arterial blood samples, as 
well as the pathological examination of the major organs were conducted by my 
colleagues. I only reference the corresponding publication here, which contain detailed 
methods description and discuss their results later on.159 
 
5.1.5 In Situ Hybridization, mRNA Quantification and 
immunocytochemistry 
 
The investigation of brain injury using in situ hybridization and immunohistochemistry 
were conducted by my colleagues and our collaborators. Therefore, I only reference the 
relevant publications here, which contain the detailed description of methods and 
discuss the results briefly later on.122,167 
 
5.1.6 Data analysis 
 
Three periods were defined for HR and MABP analysis to obtain information about 
ideal cooling kinetics: cooling induction (2 to 3.5 h post-insult), cooling maintenance 
(3.5 to 26 h post-insult) and rewarming/normothermia (26 to 48 h post-insult). Blood 
chemistry analysis was performed at baseline, at the end of HI, and at 12, 24, 36, and 48 
h post-HI. Intergroup statistical comparison of physiological measures and blood 
chemistry used linear regression and one-way ANOVA with adjustment for group 




of the other groups included Bonferroni correction. Differences between the 30 °C 
group and the other groups are reported with a 98.3% confidence intervals (CI). For 
non-normally distributed data, the Kruskal–Wallis rank test was used. Results are mean 
(±SD) unless stated otherwise; statistical significance was assumed for p < 0.05. 
 
5.2 Rodent experiments 
 
5.2.1 Animal preparations 
 
All experiments were carried out under the European Communities Council Directive of 
24 November 1986 (86/609/EEC) and were reviewed and approved by the Animal 
Welfare Committee of the Institute of Experimental Medicine, Budapest, Hungary. 
Wistar rat pairs (Charles River Laboratories, Hungary) were time-mated and housed 
under 12/12 light-dark cycles in a temperature (22 ± 2°C) and humidity (60 ± 10%) 
controlled environment with ad libitum access to laboratory rat food (Sniff 
Spezialdiaeten GmbH, Soest, Germany) and tap water. Fathers were removed from the 
cages on E19 of the pregnancy. On the day of birth litters were culled to 8-12 pups. A 
total of 194 pups were used for the experiments. On postnatal day 3 (P3) pups were 
tattooed on their feet for identification. On P7 pups were separated from their dams 
(except for unseparated controls) and transferred to temperature-controlled chambers 
with individual cells maintained at 37 +/- 0.5 ºC ambient temperature (except for pilot 
experiments, see below). The rectal temperature of one sentinel animal from each 
asphyxia group was continuously monitored (Physitemp Instruments, Clifton, NJ), 
which was later excluded from the analysis. Preliminary experiments showed that 
temperature variability within experimental groups was minimal, hence the sentinel 
temperature could be used as a reliable surrogate marker for the whole group. Following 
a 20-minute accommodation period the pups were subjected to control or asphyxic gas 
mixtures for 15 mins (room air or 4% O2, 20% CO2, 76% N2, respectively) and were 
allowed to recover for 60 mins before returning to their dams. This model procedure 
was originally developed by Prof Kai Kaila’s group.168 Early outcome groups were 




Surviving rats were weaned from their dams at P21 and housed in groups of 
three or four male animals in plastic cages measuring 59.5 × 38 × 22 cm (1354G, 
Eurostandard Type IV) prior to experiments. Females were excluded from behavioral 
experiments due to the large variability in behavioral phenotypes resulting from the 
estrous cycle. The animals were kept under reversed day–night schedule (lights off at 
10:00 h, lights on at 22:00 h) since rats are naturally active during night hours. 
Habituation to the reverted light/dark cycle lasted at least 2 weeks.  
 
5.2.2 Blood biochemistry and tissue cytokine measurements 
 
Rats were sacrificed either on P7 (3 or 8 h post-HI), or on P8 (24 h post-HI) for 
cytokine and blood biochemistry analysis. Following intraperitoneal injection of 
ketamine-xylazine (100 mg/kg and 10 mg/kg, respectively) and subsequent 
thoracotomy, approximately 500 uL of blood was collected from the right ventricle into 
heparinized syringes and centrifuged at 4 °C, 200 RCF for 5 minutes. Serum was 
separated, frozen and stored until analysis. 
 After transcardial perfusion with phosphate-buffered saline (PBS), liver, kidney, 
spleen, lung and small intestine samples were collected. Urine was also collected when 
possible via direct bladder puncture. All samples were frozen and stored until analysis. 
 Serum samples were analyzed for Na+, K+, Cl-, glucose, carbamide, creatinine, 
total protein, albumin, GOT, GPT levels and urine samples for Na+, K+, Cl-, glucose, 
carbamide, creatinine, and total protein content. 
 Tissue samples were homogenized and analyzed for IL-6 and CXCL-1 levels 
using ELISA (DuoSet ELISA kits, R&D Systems, Minneapolis, MN), and IL-1β and 
TNF-α levels using cytometric bead assays (CBA Flex Sets, BD Biosciences, New 
Jersey, NJ). Total protein content was quantified using the Pierce BCE Protein Assay 
(Thermo Scientific, Waltham, MA). All tests were carried out according to 
manufacturer’s instructions. 
 
5.2.3 Histology and immunohistochemistry 
 




i.p. injection of a ketamine-xylazine mixture, the animals were perfused transcardially 
with PBS and cold 4% PFA. Brains were removed and placed in 4% PFA with 20% 
sucrose for 24 h post-fixation. Afterwards brains were transferred to 20% sucrose in 
PBS and cut on a sliding microtome within 48 hours. Sequential brain slices of 40 µm 
thickness were kept in antifreeze solution at -20°C until staining. The following markers 
were used for immunohistochemistry: rabbit anti-IBA1 (1:500, Wako Chemicals, 
Germany), mouse anti-NeuN (1:1000, Merck Millipore, Darmstad, Germany), 
biotinylated lectin (1:100, Sigma-Aldrich - Merck, Darmstad, Germany), rabbit anti-
cleaved caspase 3 (1:500, Cell Signaling Technology, Danvers, MA), rabbit anti-
annexin-V (1:500, Novus Biologicals, Littleton, CO), rabbit anti-MBP (1:500, Abcam, 
Cambridge, UK), mouse anti-SMI-32 (1:1000, BioLegend, San Diego, CA), goat anti-
ICAM-1 (1:250, R&D Systems, Minneapolis, MN), rabbit anti-NFκB (1:500, Abcam, 
Cambridge, UK), rabbit anti-c-FOS (1:500, Santa Cruz Biotechnology, Dallas, TX), 
rabbit anti-HIF-1a (1:500, R&D Systems, Minneapolis, MN), mouse anti-CD-45 (1:200, 
BD Biosciences, New Jersey, NJ). After washing and blocking with 2% normal goat or 
donkey serum (plus 0,3% H2O2 for peroxidase quenching in case of 3,3'-
Diaminobenzidine staining), incubation with primary antibodies was done overnight. 
Slices were washed and incubated with secondary antibodies (either fluorescent or 
biotin-conjugated) for 2 hours. After washing, fluorescently labelled slices were 
mounted on glass slides and covered with Moviol solution under cover slips. 3,3'-
Diaminobenzidine (DAB) staining was completed by incubating the slices with avidin-
biotin complex for 1 hour and exposure to DAB for 20 minutes. Slices were mounted on 
glass slides and covered with gelatine solution under cover slips. 
Histological analysis was performed blindly by me and two other experimenters, 
using standard light microscopy for DAB stained slices and epifluorescent or confocal 
microscopy for fluorescently labelled slices. Positive cells were manually counted on all 
the slices which contained the pre-designated areas of interest.  
 
5.2.4 Behavioral testing 
 
Each animal performed in 2 behavioral tests, while weighing 250–400 g (at the age of 




dim red illumination, except for the Delayed Discounting test. 
 
Figure 4: Illustrations of neuromotor tests. (A) Open Field; (B) Elevated Plus Maze; (C) 
Rotarod.† 
The neuromotor test paradigms are illustrated on Figure 4. The Open Field (OF) 
test was used to evaluate locomotion and anxiety. In this test, the animals are placed in 
the middle of a round box and their behavior is observed for 10 minutes. The OF box 
was a round wooden area (diameter 90 cm) surrounded by a metal wall (40 cm), painted 
dark grey.  
The elevated plus-maze (EPM) test was also used to investigate locomotion and 
anxiety. In this test, the animals are placed in the middle of a plus-shaped maze and their 
behavior is observed for 5 minutes. The EPM field was made of wood (painted dark 
grey) and consisted of two opposite open arms (50 × 20 cm) and two enclosed arms (50 
× 20 × 30 cm), elevated to a height of 80 cm above the floor. The junction area of the 
four arms (central area) measured 20 × 20 cm. Rats were placed on the central area 
facing a closed arm at the beginning of the test.  
For both tests, the testing apparatus was cleaned thoroughly between subjects 
with wet and dry towels. Behavior was video-recorded by an overhead light sensitive 
camera placed 2 m above the testing apparatus and analyzed by a computerized video-
tracking system (Ethovision Pro, Noldus Information Technologies, Wageningen, The 
Netherlands). 
Motor coordination was assessed using a Rota-rod apparatus (InsightR, Brazil) 
                                                 





according to Rojas et al.170  In this test, the animals are taught to maintain their balance 
on a rotating horizontal rod (3 cm diameter). Animals were exposed to one habituation 
session in five trials of maximum 3 min each with the apparatus on slow velocity (4 
rpm). In the test session, 24 h later, animals’ motor ability was evaluated. The rota-rod 
test was performed by placing rats on the rotating drums and measuring the time each 
animal was able to maintain its balance on the rod. The speed of the rota-rod accelerated 
from 4 to 25 rpm over a 3 min period. Variables recorded were: latency of the first 
downfall, number of falls (maximum 5). 
 
 
Figure 5: The Operant Learning – Delayed Discounting test. (A) Photograph showing the 
Operant learning apparatus (“Skinner Box”). (B) The procedure of the Delayed Discounting 
test. 
The delay discounting test (DD) was used to assess learning and impulsive 
behavior (Figure 5). This test was conducted using automated operant chambers 
equipped with two nose-poke holes with infrared sensors and LED lights, a chamber 
light and a feeder device with a magazine into which food pellets were dropped (Med 
Associates, St. Albans, VT, USA). Chambers were placed inside sound-attenuated 
wooden cubicles and were controlled via computers running Med-PC IV software (Med 
Associates, St. Albans, VT, USA). Rats were always trained and tested in the same 
operant box because even small changes in the environment can have deleterious effects 
on the training. After each session ended, the chambers were cleaned with tap water and 
were dried with paper towels. All experiments were conducted in the early hours of the 
dark phase. 
 
5.2.4.1 Delayed Discounting procedure 
 




subjects was restricted throughout the study to increase their motivation for food 
rewards. During the training phase, animals were placed inside a chamber for 30 min 
daily for 5 days. A response on one of the nose-poke holes was rewarded with one 45 
mg food pellet (small reward), while a response on the other hole resulted in five 45 mg 
food pellets (large reward). Both types of reward were presented immediately after the 
response and were followed by a 25 s timeout (TO) with the chamber light switched on. 
Chamber light was used as a cue which could be associated with the reward after 
responding on one of the nose-poke holes.171 During the timeout period, responses were 
not rewarded but were registered. To avoid side preference, the nose-poke hole on 
which responding was rewarded with five food pellets was randomly assigned to either 
the left or the right side between animals. Animals were placed in the same chamber 
with the same nose-poke hole side assignment throughout the experiment. At the end of 
the training phase, the animals were expected to respond on the nose-poke hole that was 
paired with the large reward in approximately 90% of all trials.171 
After two days of rest, the animals underwent the test phase. During this phase, 
each animal was placed in a chamber for 30 min daily for 8 days. The procedure was 
similar to that described for the training phase, but a delay was inserted before the large 
reward (Figure 5B). The delay was fixed for each daily session and was increased 
progressively over subsequent days (10, 20, 30, 45, 60, 80, 100 and 120 s). Responses 
during these delays were not rewarded, but they were recorded by the software. 
Sessions of the test phase were conducted at the same time as sessions of the training 
phase. During the test phase, subjects were expected to shift their preference from the 
nose-poke hole rewarded by the delayed large reward to the nose-poke hole rewarded 
by the immediate small reward.171 
During the training sessions, we recorded the preference of the nose-poke hole 
paired with the large reward (large reward preference) to assess learning capabilities. 
Increases of greater magnitude in large reward preference indicated quicker learning. 
During the test phase, large reward preferences were indicative of non-impulsive 
choices. This variable is negatively associated with choice impulsivity, which refers to 
an inability to prefer a larger, delayed reward over an immediate smaller one.172 The 
number of inadequate responses (the sum of responses during timeouts and delays), 




this measure, we were able to assess motor impulsivity, which is defined as the inability 
to inhibit inappropriate actions.172 
All behavioral tests were analyzed by automated tracking software (Ethovision 
Pro, Noldus Information Technologies, Wageningen, The Netherlands) or the H77 event 
recorder software. 
 
5.2.5 Statistical analysis 
 
Data were processed and analyzed using the GraphPad Prism 5 software. Where normal 
distribution could be assumed, Student’s t-test was used and the data is displayed as 
mean + standard error. In cases where normality could not be assumed, the Mann-
Whitney U-test and the Kruskal-Wallis rank test were used and data is displayed as 
median + inter-quartile range. Where in addition to treatment, another repeated factor 
was also present, repeated-measures two-way ANOVA was used with post-hoc testing 




6.  RESULTS 
 
6.1 Cooling to different target temperatures in a piglet model of HIE 
 
These experiments were conducted at the University College London, UK, using a 
preclinical piglet model of neonatal HIE. 
 
6.1.1 General characteristics 
 
We found no differences between the groups regarding body weight, postnatal age, 
insult severity or baseline physiological and biochemical parameters (Table 2). Six 
piglets cooled to 30 °C suffered an episode of cardiac arrest and five of these died 
before 48-h post-HI due to a combination of pulmonary edema, fluid in the thorax or 
abdominal cavities, severe metabolic derangement, or profound hypotension. One 
animal cooled to 33.5 °C suffered two cardiac arrests but survived to 48 h. There was 
one recorded incidence of persistent arrhythmia in the 30 °C group. 
Table 2: Physiological parameters for piglets in each temperature group. Mean (SD) values are 
presented for each group. Linear regression with adjustments to baseline and one-way ANOVA 
and post-hoc analysis were carried out on comparisons between groups with Tukey’s and 
Dunett’s method. Time zero was set at the start of resuscitation after the hypoxic–ischemic 
insult. The insult severity index was defined as the time integral of the acute energy depletion 
during HI and for 60 min of resuscitation. AED, acute energy depletion; HI, hypoxia–ischemia; 
HR, heart rate; MABP, mean arterial blood pressure; Trec, rectal temperature; a: P < 0.05 vs. 
normothermia at the same time point or during the same time period; b: P < 0.05 vs. 35 °C at 
the same time point or during the same time period; c: P < 0.05 vs. 33.5 °C at the same time 
point or during the same time period; d: P < 0.01 in cross-group comparisons. 
Variables Normothermic 35 ºC 33.5 ºC 30 ºC 
Postnatal age (h) 22.3 (1.2) 22.6 (1.1) 22.7 (0.9) 22.5 (1.1) 
Body weight (g) 1771 (132) 1786 (90) 1714 (146) 1864 (180) 
AED (h, insult severity) 0.07 (0.04) 0.05 (0.03) 0.06 (0.04) 0.08 (0.07) 




Baseline 158 (26) 162 (32) 152 (28) 144 (21) 
End of insult 182 (28) 184 (30) 187 (32) 172 (29) 
2-3.5 h after time zero 155 (28) 130 (26) 132 (30) 130 (11) 
3.5-26 h after time zero 156 (15) 121 (28) 114 (21) 
123 (16)  
a 
26-48 h after time zero 151 (22) 146 (33) 140 (17) 149 (4) 
MABP (mmHg)     
Baseline 51 (6) 53 (7) 53 (9) 51 (6) 
End of insult 51 (10) 59 (16) 58 (11) 55 (6) 
2-3.5 h after time zero 45 (6) 43 (5) 44 (8) 47 (7) 
3.5-26 h after time zero 51 (6) 48 (6) 47 (6) 43 (7) 
26-48 h after time zero 52 (6) 51 (7) 47 (6) 48 (11) 
Trec (°C)     
Baseline 38.4 (0.4) 38.2 (0.6) 38.1 (0.8) 38.4 (0.4) 
End of insult 38.2 (0. 4) 38.1 (0.3) 38.1 (0.4) 38.2 (0.4) 
6-26 h after time zero 38.5 (0.4) 
34.9 (0.4)  
a d 
33.2 (0.5)  
a b d 
30.2 (0.4)  
a b c d 
26-48 h after time zero 38.4 (1.3) 37.7 (1.2) 
37.0 (1.8)  
a b d 
34.4 (2.6)  
a b c d 
 
6.1.2 Cardiovascular parameters 
 
During the induction of cooling and the rewarming/normothermia phases, HR and 
MABP were similar in all of the groups (Table 2). The baseline heart rate averaged over 
all groups was 154 (17) beats per minute (bpm). In the 35 °C and the 33.5 °C groups, 
HR was unchanged during hypothermia as well, but in the 30 °C group, HR was 







Figure 6: Summary of heart rate and mean arterial blood pressure changes. Mean % change 
in (A) heart rate (HR) and (B) mean arterial blood pressure (MABP) during and after 24-h 
whole-body hypothermia for each temperature group: 38.5 °C (normothermia, purple circles), 
35 °C (green squares), 33.5 °C (blue triangles) and 30 °C (red upside-down triangles). The blue 
box represents the duration of the cooling period. Error bars are omitted for clarity. 
*Significant difference between the 30 °C and the normothermia groups (p < 0.0001). Nadir: 
hypoxia mid-point; 0 h: end of hypoxia-ischemia. 
 
We found periods of profound hypotension (~30 mm Hg) in the 30 °C group that 
lasted for several hours. These periods usually preceded a cardiac arrest and were 
generally seen in the five 30 °C animals which died before 48 hours. However, when 
averaged over the analysis periods, these hypotensive episodes did not alter the overall 
picture significantly and the MABP of the 30 °C animals was similar to the other 
cooling groups (Figure 6B). 
 Two of the normothermic animals required volume replacement after HI; these 
animals required no inotropes. The median overall volume replacement (saline and 
Gelofusin combined) was significantly higher in the 30 °C group compared to the 
normothermic group (p = 0.05, Table 3). The median dopamine infusion dose over 48 h 
was higher in the 30 °C group than in the normothermia (p = 0.01) or in the 33.5 °C 
hypothermia (p=0.05) groups. The median dopamine infusion dose was also higher in 
the 33.5 °C group compared to normothermic animals (p = 0.05). Additionally, multiple 
inotrope infusions (dopamine, dobutamine and noradrenaline) were required during 




necessary in all other groups.  
Table 3: Summary of volume replacement and inotrope use. Median (Interquartile range) total 
volume replacement (ml/kg) and inotrope dose (ug/kg/min) are shown over the 48-hour period 
following hypoxia-ischemia according to each temperature group. Kruskal-Wallis equality-of-
populations rank test was used and a ‘0’ value was assumed for periods when no inotropes were 
given; a: p<0.05 vs normothermia at the same time point or during the same time period; b: 




35 ºC 33.5 ºC 30 ºC 
Volume replacement 
(ml/kg) 
15 (0, 31) 19 (0, 38) 18 (0, 82) 
70 (46-108)  
a 
Inotropes (ug/kg/min)     
Dopamine  0 (0, 0) 0 (0, 4.8) 
5.5 (0.7, 11.1)  
a 
13.8 (8.2, 18.6) 
 a b 
Dobutamine  0 (0, 0) 0 (0, 0) 0 (0, 0) 16.0 (0, 18.7) 
Noradrenaline  0 (0, 0) 0 (0, 0) 0 (0, 0) 0.1 (0, 0.3) 
 
6.1.3 Changes in blood biochemistry parameters 
 
Blood pH was lower in the 30 °C group at 36 h compared to the normothermic group (p 
= 0.05) and also at 12 h with borderline post hoc significance (p = 0.05, Table 4 and 
Figure 7A). Base deficit was increased in the 30 °C group at 12, 24 and 36 h compared 
to all other groups (all p < 0.05, Table 4 and Figure 7B), while it was similar among all 
other groups at these time points.  
Table 4: Blood gas variables for piglets in each temperature group. Mean (SD) or median 
(Interquartile range) values are presented. Linear regression with adjustments to baseline and 
one-way ANOVA and post-hoc analysis was carried out on comparisons between groups with 
Tukey’s and Dunett’s method. Time zero was set at the start of resuscitation. The insult severity 
index was defined as the time integral of the acute energy depletion during HI and for 60 min of 
resuscitation. HI, hypoxia–ischemia; PaCO2, partial arterial pressure of carbon dioxide; PaO2, 
partial arterial pressure of oxygen; a: P < 0.05 vs. normothermia at the same time point or 
during the same time period; b: P < 0.05 vs. 35 °C at the same time point or during the same 
time period; c: P < 0.05 vs. 33.5 °C at the same time point or during the same time period; d: P 








35 ºC 33.5 ºC 30 ºC 
PaO2 (kPa)     
Baseline 
9.3 (1.1)  
f 
10.5 (1.7) 9.4 (1.9) 8.3 (1.7) 
nadir of the 
insult 
3.3 (1.0)  
e f 
3.1 (1.1)  
e 
3.1 (1.2) 
3.0 (1.0)  
e 
12 h after time 
zero 
10.3 (1.2)  8.8 (1.2) 9.2 (5.3) 8.0 (2.9) 
24 h after time 
zero 
11.2 (2.6)  
e 
12.3 (6.3) 9.8 (3.3) 7.5 (2.2) 
36 h after time 
zero 
10.9 (2.2) 10.0 (3.6) 11.5 (4.5) 8.9 (1.7) 
48 h after time 
zero 
11.7 (2.2) 11.6 (3.0) 14.2 (6.3) 11.7 (1.9) 
PaCO2 (kPa)     
Baseline 5.46 (0.74) 5.26 (1.05) 5.26 (0.65) 4.98 (0.76) 
nadir of the 
insult 
4.36 (0.49) 4.88 (1.22) 5.27 (0.94) 5.02 (0.82) 
12 h after time 
zero 
5.29 (0.93) 4.81 (0.71) 6.17 (0.86) 5.83 (2.13) 
24 h after time 
zero 
4.23 (1.03) 6.08 (1.71) 4.96 (1.34) 4.82 (2.43) 
36 h after time 
zero 
5.29 (1.11) 5.68 (1.36) 6.80 (1.26) 6.82 (1.35) 
48 h after time 
zero 
5.21 (1.28) 5.15 (0.71) 6.15 (1.43) 4.47 (0.51) 
pH     
Baseline 7.49 (0.04) 7.50 (0.09) 7.52 (0.06) 7.51 (0.07) 
nadir of the 
insult 
7.47 (0.09) 7.44 (0.05) 7.43 (0.16) 7.44 (0.08) 
12 h after time 
zero 
7.57 (0.08)  7.54 (0.09) 7.45 (0.05)  7.37 (0.20)  
24 h after time 
zero 
7.59 (0.09)  7.45 (0.14) 7.48 (0.14) 7.37 (0.28) 
36 h after time 
zero 
7.47 (0.10) 7.45 (0.10) 7.37 (0.10) 
7.29 (0.11)  
a 
48 h after time 
zero 
7.45 (0.11)  
f 









Baseline 8.2 (3.6) 7.8 (2.1) 9.6 (5.4) 7.5 (4.5) 
Nadir of the 
insult 
0.7 (5.4)  
e f 
0.0 (4.0)  
e f  
2.2 (8.0) 1.2 (3.0) 
12 h after time 
zero 
11.7 (3.3)  9.7 (1.0)  9.3 (2.7) 
0.6 (8.8)  
a b c d 
24 h after time 
zero 
8.5 (3.7) 7.2 (2.6) 3.6 (5.5) 
-5.5 (8.8)  
a b c d 
36 h after time 
zero 
6.1 (3.0) 5.6 (1.5) 3.6 (3.8) 
-3.1 (6.0)  
a b c 
48 h after time 
zero 
3.6 (4.0) 5.0 (2.6) 2.1 (4.0) 4.5 (5.4) 
Lactate 
(mmol/L) 
    
Baseline 3.4 (2.6, 4.3) 
3.7 (2.9, 4.0)  
f  
2.7 (2.4, 5.5) 3.3 (2.8, 3.8) 
Nadir of the 
insult 
7.6 (6.47, 8.5)  
e f 
7.4 (6.7, 8.4)  
e f  
6.9 (6.0, 9.7)  
e f  
8.2 (6.7, 9.0) 
12 h after time 
zero 
1.8 (1.3. 1.9) 
1.6 (1.1, 1.9)  
e  
1.3 (0.7, 1.7)  2.2 (1.7, 10.0)  
24 h after time 
zero 
2.4 (1.6, 3.0) 
1.6 (0.9, 1.7)  
e 
1.8 (1.5, 3.3) 3.6 (2.1, 12.0)  
36 h after time 
zero 
1.0 (0.8, 1.7) 1.5 (1.5, 1.6) 1.1 (1.0, 1.4) 2.7 (1.5, 3.8) 
48 h after time 
zero 
1.3 (1.2, 1.4) 
1.3 (1.1, 2.1)  
e 
1.2 (1.1, 1.8) 2.6 (1.8, 3.2) 
Glucose 
(mmol/L) 
    
Baseline 
7.5 (6.1, 8.1)  
f  
6.8 (6.1, 7.5) 6.2 (5.7, 6.5) 
7.6 (6.9, 8.3)  
f 
Nadir of the 
insult 
9.8 (8.3, 10.4)  
e f  
7.8 (7.7, 8.9) 8.4 (7.5, 9.8) 8.5 (8.5, 9.5) 
12 h after time 
zero 
5.2 (5.0, 6.2)  
e 
5.5 (4.4, 7.0) 9.3 (4.7, 10.7) 
17.2 (9.7, 28.7) 
a b e  
24 h after time 
zero 
5.4 (4.8, 6.2)  
e  
5.4 (4.5, 9.6)       5.5 (5.1, 8.5)  
23.9 (12.2, 25.9)  
e 
36 h after time 
zero 
4.9 (4.1, 6.2) 6.4 (6.1, 7.4) 5.5 (4.3, 11.6) 15.9 (4.8, 15.9) 
48 h after time 
zero 
4.8 (3.9, 5.2)  4.9 (4.7, 5.2) 4.3 (3.0, 5.5) 








Figure 7: Summary of blood pH and base excess values. Mean blood pH (A) and base excess 
(B) are displayed at baseline, nadir, 12, 24 36 and 48 h post-HI for each temperature group: 
38.5 °C (normothermia, purple circles), 35 °C (green squares), 33.5 °C (blue triangles) and 30 
°C (red upside-down triangles). The blue box represents the duration of the cooling period. 
Error bars are omitted for clarity. *Significant difference between the 30 °C and all other 
groups (p < 0.05) at 12, 24 and 36 h. Nadir: hypoxia mid-point; 0 h: end of hypoxia-ischemia.  
 
 Blood glucose was significantly higher in the 30 °C group at 12 h compared to 
either the normothermic or the 35 °C groups (p = 0.05 in both cases). Since findings of 
hyperglycemia were always treated according to clinical protocols outlined in the 
Methods section, the glucose levels of the 30 °C group normalized by the end of the 
cooling period at 24 h (Table 4 and Figure 8A and B). Blood lactate reached its highest 
levels at 24 h in the 30 °C group, but it was not significantly different from the other 
groups (Table 4 and Figure 8C and D). We found lower blood potassium levels in the 
30 °C group at 12 h as compared to the 35 °C and the 33.5 °C groups (p = 0.01 and p = 
0.05, respectively). Hematocrit was found to be higher in the 30 °C group at 24 h 
compared to the normothermic and 33.5 °C groups (p = 0.05 in both cases) and 
hemoglobin was also greater in the 30 °C group at 12 h as compared to the 35 °C group 





Figure 8: Glucose and lactate values. Levels of median (A & B) blood glucose and (C & D) 
lactate are shown 12 and 24 h after HI. *Significant difference between the 30 °C group and the 
normothermia and 35 °C groups for glucose only (p < 0.05). HI: hypoxia-ischemia. Values are 





Table 5: Blood chemistry for piglets in each temperature group. Mean (SD) or median 
(Interquartile range) values are presented for each group. Linear regression with adjustments to 
baseline and one-way ANOVA and post-hoc analysis was carried out on comparisons between 
groups with Tukey’s and Dunett’s method. Time zero was set at the start of resuscitation after the 
hypoxic–ischemic insult. The insult severity index was defined as the time integral of the acute 
energy depletion during HI and for 60 min of resuscitation. HI, hypoxia–ischemia; a: P < 0.05 
vs. normothermia at the same time point or during the same time period; b: P < 0.05 vs. 35 °C 
at the same time point or during the same time period; c: P < 0.05 vs. 33.5 °C at the same time 
point or during the same time period. 
Variables Normothermic 35 ºC 33.5 ºC 30 ºC 
Sodium (mmol/L)     
Baseline 133.4 (3.4) 131.3 (3.6) 130.2 (2.6) 130.7 (2.9) 
Nadir of the insult 132.0 (3.6) 131.3 (4.7) 130.2 (3.7) 130.8 (3.5) 
12 h after time zero 128.3 (3.2) 125.7 (3.6) 126.3 (2.7) 128.7 (8.5) 
24 h after time zero  127.9 (3.0) 124.3 (3.6)  125.0 (3.7) 124.6 (6.9) 
36 h after time zero 128.4 (6.9) 122.8 (5.7)  125.4 (2.2) 127.1 (3.3) 
48 h after time zero 128.1 (8.0) 125.8 (1.9) 126.1 (4.5) 130.3 (3.6)  
Potassium (mmol/L)     
Baseline 3.76 (0.69) 4.49 (1.11) 4.96 (0.54) 3.87 (1.42) 
Nadir of the insult 3.92 (0.82) 4.55 (1.15) 5.22 (1.07) 3.68 (1.10) 
12 h after time zero 
4.95 (0.77) 5.76 (0.71) 5.25 (0.77) 3.89 (0.92)  
b c 
24 h after time zero  4.77 (0.89) 5.31 (1.24)  5.47 (1.32) 4.38 (1.13) 
36 h after time zero 4.93 (0.09) 6.02 (0.14)  5.84 (0.14) 5.14 (0.28) 
48 h after time zero 5.36 (1.03) 5.08 (1.44) 5.60 (1.53) 4.75 (0.50)  
Chloride (mmol/L)     
Baseline 99.6 (3.3) 99.7 (2.8) 99.4 (3.2) 97.5 (2.5) 
Nadir of the insult 101.0 (4.4) 100.7 (4.0) 99.8 (2.9) 97.4 (2.9) 
12 h after time zero 98.3 (3.9) 96.9 (2.8) 96.5 (3.2) 97.3 (8.1) 
24 h after time zero  97.7 (3.9) 94.7 (3.1)  97.4 (1.9) 95.0 (2.3) 
36 h after time zero 100.1 (7.0) 95.8 (4.0)  98.0 (2.3) 100.0 (5.8) 
48 h after time zero 100.0 (7.4) 96.3 (2.4) 99.0 (2.3) 101.0 (3.7)  
Hematocrit     
Baseline 28.6 (10.6) 24.6 (3.3) 24.7 (4.7) 23.6 (6.0) 
Nadir of the insult 22.8 (4.0) 29.6 (9.3) 29.6 (9.3) 28.4 (5.7) 
12 h after time zero 23.8 (7.4) 22.3 (4.4) 27.7 (3.3) 29.3 (10.4) 





36 h after time zero 21.0 (3.8) 22.4 (3.2)  19.4 (5.0) 23.4 (5.5) 
48 h after time zero 22.0 (4.5) 23.5 (7.3) 18.4 (5.3) 19.3 (5.6)  
Hemoglobin (g/dL)     
Baseline 6.7 (3.6) 8.3 (1.1) 8.4 (1.6) 8.1 (2.0) 
Nadir of the insult 7.8 (1.4) 7.8 (1.4) 10.0 (3.2) 9.6 (1.9) 
12 h after time zero 
8.1 (2.5) 7.6 (1.5) 9.4 (1.1) 11.1 (2.2)  
b 
24 h after time zero  
7.7 (1.2) 9.4 (2.0)  7.7 (1.7) 10.8 (2.3)  
a 
36 h after time zero 7.1 (1.3) 7.6 (1.1)  6.6 (1.7) 8.0 (1.9) 
48 h after time zero 7.5 (1.6) 8.0 (2.5) 6.7 (1.4) 6.6 (1.9)  
Creatinine (mmol/l)     
Baseline 0.60 (0.13) 0.59 (0.07) 0.65 (0.24) 0.56 (0.07) 
Nadir of the insult 0.58 (0.17) 0.53 (0.08) 0.64 (0.18) 0.52 (0.16) 
12 h after time zero 0.73 (0.27) 0.90 (0.16) 0.95 (0.31) 0.80 (0.26) 
24 h after time zero  0.94 (0.61) 1.20 (0.23)  0.99 (0.55) 1.2 (0.42) 
36 h after time zero 1.17 (0.61) 1.38 (0.26)  1.50 (0.61) 1.24 (0.18) 
48 h after time zero 1.53 (0.73) 1.54 (0.79) 1.57 (0.71) 1.00 (0.37)  
 
 Shivering episodes unrelated to seizures occurred with similar frequency in all 
groups. The cortisol measurements conducted by my colleagues did not reveal any 
differences between the groups at any timepoints, although there was a trend-like 
increase of cortisol levels 2 h after HI and a similar decrease at 12 h (during the cooling 
phase) after HI. The cardiac troponin-I measurements conducted by my colleagues 
showed decreased levels in the 30 °C group compared to other groups over the 12-48 h 
period following HI (p ≤ 0.01). The figures for this data can be found in the original 
publication.159 
 
6.1.4 Ex vivo investigations 
 
These studies were conducted by my colleagues and collaborators using the tissue 
samples generated from the experiments detailed before. Macroscopic organ pathology 
was evaluated by an expert pathologist. Any kind of macroscopic organ pathology was 




and 30 °C groups, respectively (Table 6). Patchy sinousoidal congestion of the liver was 
the most common pathological finding across all groups. Evidence of pneumonia was 
observed in all groups except the 30 °C group and vacuolated kidneys in all but the 
normothermic group. The occurrences of acute tubular necrosis and liver steatosis were 
limited to the 33.5 °C and the 30 °C group only. No evidence of macroscopic pathology 
was noted in the hearts of the 33.5 °C and the 30 °C group. No organ pathology was 
noted in two naïve piglets, who did not undergo any experimental procedures. 
Table 6: Macroscopic organ pathology following hypoxia-ischemia and survival to 48 hours 
according to temperature group. A subset of 27 piglets and 2 naïve piglets organs (lungs, liver, 
kidney, spleen, pancreas and heart) were assessed for macroscopic pathology (x4 and x40 
magnification) and incidence of remarkable pathology per individual were noted. * Only 4 
hearts were available for analysis (33.5 °C, 30 °C, 2x naïve). 
 
The in situ hybridization studies were conducted by our collaborators. The 
results were published elsewhere and the reader is referred to that article for the detailed 
description.167 Briefly, these studies focused on eight mRNA transcripts relevant for 
perinatal brain injury (BDNF, MANF, GFAP, MAP2, HSP70, NgR, LDH-A, LDH-B) 
and found that most of them were significantly affected by HI. Hypothermia 
counteracted this affect to a certain degree in most brain areas. In some instances it was 






































































indicated that cooling to 33.5 °C conferred the most benefit when compared to 35 °C 
and 30 °C. Deep hypothermia to 30 °C made the effect of HI even more severe in 
certain brain regions.167 
The histological and immunohistochemical analysis of the collected brain 
samples were performed by my colleagues and published separately; the details of this 
study can be found in that article.122 Briefly, markers of necrotic and apoptotic neuronal 
death as well as microglial activation markers showed that cooling to 35 °C and 33.5 °C 
both effectively ameliorated hypoxic-ischemic brain damage, while this effect was 





6.2 Investigating endogenous hypothermia in a rodent model of HIE 
 
These experiments were conducted at the Institute of Experimental Medicine, Budapest, 
Hungary, using a novel rodent model of neonatal HIE adopted from Prof Kai Kaila’s 
group.166 
 
6.2.1 Effect of ambient temperature on neonatal asphyxia tolerance 
 
During our pilot experiments, we first examined the effect of ambient 
temperature on the asphyxia tolerance of neonatal rat pups. We found that chamber 
water temperature was the best surrogate marker for ambient temperature, as various air 
temperature monitors displayed significantly different values and were slow to respond. 
We used three chamber temperature ranges: 30-31 °C, 33-34 °C, and 36-37 °C. We also 
performed one experiment at room temperature (21.2 °C) without heating, but excluded 
it due to the lack of observable signs of distress (gasping, laborious breathing, 
respiratory arrest) after 45 minutes of asphyxia. All experiments were conducted under 
otherwise similar conditions. The neonatal ventilatory response to hypoxia consists of 
the following stages: (1) immediate hyperventilation; (2) hypoventilation and gasping; 
(3) fast and shallow gasping; (4) terminal apnea.173  The asphyxic insult was terminated 
when at least two animals entered the third stage of respiratory failure and this duration 
was considered the experimental group’s asphyxia tolerance. 
We found that on average, insult duration could be extended to 45 minutes at 30-
31 °C, 27.5 minutes at 33-34 °C and 15 minutes at 36-37 °C ambient temperatures 
(Figure 9A). Since these were pilot experiments and the 30-31 °C and 33-34 °C groups 
involved only 3 and 2 sentinel animals respectively, this study was not powered to 
determine statistical differences between the temperature groups. Considering the fixed 
temperature environment of intrauterine asphyxia, where the fetal temperature cannot 
decrease below the maternal,174 we chose to conduct all subsequent experiments at 37 ± 





Figure 9: Summary of the preliminary temperature experiments. (A) shows the average length 
of the asphyxic insult in ambient (chamber) temperatures between 36-37 °C (n=20), 33-34 °C 
(n=2) and 30-31 °C (n=3). (B) shows the observed reduction of rectal temperature in the 
different ambient temperature groups during asphyxia. The dotted line shows the average 
chamber temperature. Values are displayed as mean + SEM. 
 
6.2.2 Role of endogenous hypothermia 
 
In the 36-37 °C group the average chamber temperature in the preliminary experiments 
was 35.3 (1.44) °C. Upon transfer to the chambers, pups had a Trec of 33.8 (0.97) °C. 
At the end of the 20 min baseline accommodation period, the mean Trec was 37.1 (0.5) 
°C. During 15 minutes of asphyxia, we observed a gradual decrease of mean Trec to 
35.8 (1.03) °C (Figure 9B), consistent with the hypoxic hypometabolism response. A 
similar decrease in rectal temperature during asphyxia was observed in both other 
temperature groups (Figure 9B). 
 In order to determine the influence of chamber temperature on this phenomenon, 
we calculated the difference between the chamber temperature and the Trec for each 
litter. At the beginning of asphyxia, the animals were on average 1.78 (1.13) °C warmer 
than the set chamber temperature. However, this difference was significantly reduced by 
the end of asphyxia (0.48 (1.14) °C, p < 0.0001, Figure 9B, dotted red line). We have 
also made similar observations in the other ambient temperature groups, consistent with 





6.3 Characterization of a novel rodent model of HIE 
 
Following the experiments concerning endogenous hypothermia, we proceeded to 
characterize this novel rodent model of neonatal HIE. 
 
6.3.1 Preliminary experiments 
 
We have conducted a set of preliminary experiments in order to identify the most 
sensitive biomarkers of HI injury. Serum and urine samples did not reveal any 
significant differences between control and asphyxia samples. Cytokine analysis of 
tissue homogenates displayed high variability and no discernable trends between the 
two groups. We also conducted preliminary immunohistochemistry using a number of 
antibodies, which are widely employed in perinatal asphyxia research. Some of these 
antibodies did not show significant alterations in response to asphyxia (eg. CD-45, 
Annexin-V, HIF-1), and therefore were not used for randomized experiments. Other 
antibodies, which appeared to be more sensitive to asphyxia (eg. IBA-1) were included 
in the randomized experiments. 
 
6.3.2 Randomized experiments 
 
Pups were randomized into control or asphyxia groups on P7. Chamber temperature was 
set to 36.5 – 37.5 °C. The baseline characteristics of the animals were similar, as 
summarized in Table 7. The higher portion of males used are due to the fact that 
behavioral analysis can be most reliably performed on males and thus we attempted to 
exclude females when litters were culled. The asphyxia group had an overall mortality 
of 20.7 % (17/82) during asphyxia, while no animals died after reoxygenation. The 
control group had no mortality during the observation period. 
Table 7: Baseline characteristics of the experimental animals used in the studies. Values are 
displayed as total number or mean (SD). 
 Control Asphyxia p-value 
Number of animals 68 82  




Weight (g) 15.1 (2.04) 15.7 (2.18) 0.157 
Mortality during 
the experiment 
0 17  
 
6.3.3 Early brain histology 
 
Brains collected 24 h after HI were used to investigate early brain injury after HIE. 
Nissl staining was conducted first in order to assess overt neuronal death throughout 




Figure 10: Nissl staining. Representative photomicrographs of Nissl staining from the (A-C) 






In addition to neuronal death, white matter damage and axonal injury was assessed 
using MBP and SMI-32 immunohistochemistry, respectively (Figure 11). We found no 
difference between the control and the asphyxia group with either staining. 
 
Figure 11: MBP and SMI-32 immunohistochemistry. (A-B) MBP immunohistochemistry of the 
striatum and external capsule showing no difference between (A) control and (B) asphyxic 
animals. (C-D) SMI-32 staining showing no signs of axonal injury in either the (C) control or 
the (D) asphyxia group. MBP: myelin basic protein; SMI-32: Neurofilament H Non-
Phosphorylated. 
 
In order to investigate inflammatory effects of HIE, IBA-1 immunohistochemistry was 
used to study microglial activation (Figure 12). We found an overall increase in the 
number of activated IBA-1 positive microglia in both the prelimbic- and infralimbic 




ammonis and dentate gyrus of the hippocampus (CA and DG, respectively). 
 
Figure 12: IBA-1 immunohistochemistry. (A-B) Representative photomicrographs showing an 
increased number of IBA-1 positive microglial cells in the hippocampus. (C-D) Quantification 
of the increased microglial activation in regions of the prefrontal cortex (PrL and IL) and the 
hippocampus (CA & DG), respectively (n=5-10 per group). *Significantly increased number of 
IBA-1 positive microglial cells in the asphyxia group compared to the control group (p < 0.05). 
The quantification of prelimbic microglial staining was conducted by my colleague, Barbara 
Orsolits. Values are displayed as mean + SEM. PrL: prelimbic cortex; IL: infralimbic cortex; 
CA: cornu ammonis; DG: dentate gyrus.  
 
Brains collected 3 h post-HI were also stained for cFOS and NFκB in order to 
potentially identify regions activated directly by asphyxia-induced stress. Early 
investigations using cFOS and NFκB did not reveal significant differences between the 




differences in certain areas, due to the high level of variance in both groups, no 
significant conclusions could be drawn. 
 
6.3.4 Behavioral tests 
 
First, in order to identify the most relevant control group for behavioral studies, we 
conducted the sensitive elevated plus maze test (EPM) using two control groups 
(unseparated and separated from the dam), in the interest of investigating the potential 
effect of maternal separation in addition to asphyxia. Figure 13A-B shows the results of 
the EPM test. In terms of the number of open arm entries, which is an indicator anxiety, 
(Figure 13A), we found that maternal separation had an effect of comparable size as 
asphyxia, even though this was not statistically significant. Since this could possibly 
become a confounding factor in these behavioral experiments and since there was no 
way to remove this confounder (i.e. conduct asphyxia without maternal separation), we 
opted to use maternally separated controls for all later experiments. 
The results of the Open Field test are shown in Figure 13C-D. We found no 
significant differences in locomotion between the control and the asphyxia group in 
either the EPM (number of closed arm entries,  Figure 13A) or the OF tests (total 
distance travelled, Figure 13D). In the EPM test the asphyxia group displayed a lower 
ratio of open arm entries compared to the separated control group (Figure 13B), 
indicating increased anxiety after asphyxia. Both groups spent similar time in the center 
in the OF test (Figure 13C). The Rotarod test also did not display any differences in 





Figure 13: Summary of the Elevated Plus Maze, Open Field and Rotarod tests. (A) The 
number of closed arm entries was similar between all groups in the EPM test. (B) The asphyxia 
group showed a decreased ratio of open arm entries compared to the maternally separated 
controls in the EPM test (p < 0.05). (C) In the Open Field test, the control and asphyxia groups 
spent similar time in the center, (D) and travelled similar distances in total. (E) The Rotarod test 
did not reveal any significant difference in the latency to falling off between the two groups. 
Values are displayed as median & quartiles. 
 
We used the Delayed Discounting paradigm to investigate learning and 
impulsivity in the model. During the training phase of the operant learning paradigm, 
we did not find significant differences between the learning curves of the two groups. 
(Figure 14A, left side). Similarly, when the increasing delay between the response and 
the large reward was introduced, large reward preference decreased similarly in the two 




responses (made during the delay between the nose-poke and the reward, or the 
subsequent time-out period) increased faster in the asphyxia group compared to the 
control group (p=0.08 for the interaction between the treatment and the delay, Figure 
14C), consistent with increased motor impulsivity. 
 
Figure 14: Results of the Delay Discounting test. (A) In the Operant Learning – Delayed 
Discounting paradigm, the learning curves of the control and the asphyxia group were similar, 
as the large reward preference increased during the training phase (left side) and decreased 
during the delay discounting phase (right side) similarly in both groups. (B) During the Delay 
Discounting phase of the test, however, the asphyxia group displayed a steeper increase in the 
number of inadequate responses with increasing delay between the response and the reward 





7.  DISCUSSION 
7.1 Deep hypothermia in the piglet model of HIE 
 
Our objective was to investigate the effects of deep whole-body hypothermia in a 
preclinical newborn piglet model of HIE. We have demonstrated that deep hypothermia 
of 30 ˚C leads to an abnormal metabolic homeostasis, including lactic acidosis, 
hyperglycemia and hypokalemia; an increased need for volume replacement and 
inotrope support in order to maintain normal MABP; and more fatalities compared to 
either mild hypothermia (33.5 ˚C or 35 ˚C) or normothermia. Our results reinforce the 
need for strict control of body temperature during hypothermia even under conditions of 
intensive care with special attention to avoiding inadvertent overcooling. Such 
hypothermic overshoot may occur during passive cooling as well as servo controlled 
active cooling.175,176 Our results are similar to some of the earliest clinical hypothermia 
trials, which used deep hypothermia (30 ˚C) for the treatment of head injuries and were 
discontinued because of side effects and uncertain benefits.177 
 The beneficial and neuroprotective effects of hypothermia have been discussed 
in detail in the Introduction and in a number of excellent reviews.54,60 Our experiments, 
however, have highlighted some of the potentially detrimental effects of deep 
hypothermia. Cooling has well-documented effects on the cardiovascular system, 
including peripheral vasoconstriction, sinus bradycardia with prolonged QT time, 
reduced cardiac output and decreased ejection fraction.178 Deep hypothermia is known 
to decrease heart muscle contractility by interfering with Ca2+ signaling in 
cardiomyocytes.179 However, the only cardiovascular side effect of mild cooling was 
benign sinus bradycardia in the large clinical studies of hypothermia for HIE.113 In our 
study, we have identified sinus bradycardia in the 30 ˚C group, but we have also found 
an increase in arrhythmias and in mortality, suggesting a more severe, uncompensated 
effect of deep hypothermia. Accordingly, our experiments also showed that the 30 ˚C 
deep hypothermia group required a significantly higher amount of volume replacement 
and inotrope support to maintain MABP. Current clinical protocols with moderate 




the current practice of using moderate hypothermia (33-34 ˚C) is unlikely to elicit more 
severe cardiovascular side effects. 
 Blood biochemistry and laboratory parameters have also been reported in 
clinical hypothermia trials, but the effect of cooling on these outcomes have been 
inconsistent and mild at most.113 Some trials, such as the early pilot studies of whole-
body cooling reported mild hypokalemia in the hypothermia group108 and this finding 
has also been confirmed in a number of preclinical and clinical reports.180 Some 
publications have asserted that this effect might be due to the increased adrenergic tone 
during the induction of cooling and the resulting intracellular shift of potassium.181-183 
However, the exact mechanism of this adrenergic effect is largely unknown.183 In our 
piglet experiments we have also observed hypokalemia during the cooling period in the 
30 ˚C group. This finding was rather unexpected as this group has also received the 
highest amount of volume replacement, but it is likely that adrenergic activation was 
highest in this group due to the deep hypothermia and the administered β-adrenergic 
agonists. Additionally, we have observed hyperglycemia in the 30 ˚C group, which 
might be also secondary to the increased adreno-sympathetic tone and the decreased 
metabolic rate during cooling. In adults, hyperglycemia produces increased cerebral 
injury in both human and animal studies.184 Neonatal studies are more equivocal, as a 
number of publications showed protective effects of hyperglycemia during ischemia, 
possibly due to increased substrate availability.185 Early hypoglycemia in infants with 
HIE appears to be a strong predictor of poor outcome.186 Recently, one of the large 
hypothermia trials were re-analyzed and both hypoglycemia and hyperglycemia were 
found to be independent predictors of bad outcome.187 The most recent meta-analysis of 
hypothermia trials found a significant reduction in the prevalence of hypoglycemia in 
the hypothermia group, while hyperglycemia was not observed.113 
 The increased sympathetic tone during cooling is likely unavoidable and 
probably results from the decrease in cardiac output. At the same time, maintaining 
adequate anesthesia is necessary for neuroprotection. In a preclinical trial of 
hypothermia without anesthesia, the protective effects of hypothermia were lost in 
unsedated piglets.188 In our study serum cortisol levels were not increased in either 
treatment group, indicating adequate sedation. It should also be noted that we found 




to all other groups. Since cardiac troponin-I is a robust and sensitive marker of 
cardiomyocyte injury,189 our results concur with other recent findings indicating that 
hypothermia reduces injury to cardiomyocytes.190 30 ˚C hypothermia resulted in an 
even larger decrease in troponin-I levels than 35 ˚C and 33.5 ˚C in our study, suggesting 
that deep hypothermia might be more protective for the heart muscle. However, this 
appears to come at the price of significantly depressed cardiac function and potential 
arrhythmias. 
 Certain limitations to our study should be noted. Some animal species, such as 
the dog and the piglet might be more susceptible to systemic side effects of hypothermia 
than humans.178 Additionally, the maximum decrease in core body temperature in our 
study (8.5 ˚C) was much higher than current clinical protocols indicate, corresponding 
to 28.5 ˚C in humans. The time of initiation and length of cooling was also different 
from clinical practice, which was primarily due to feasibility reasons. However, this 
model still produces brain injury which is very similar to human babies with moderate 
to severe HIE and our cooling protocol offers comparable neuroprotection to clinical 
hypothermia.191 The use of isoflurane anesthesia in combination with fentanyl analgesia 
was necessary in our case, due to animal ethics considerations. Inhalation anesthetics, 
including isoflurane has been shown to suppress cardiac function 192 and possibly also 
deliver neuroprotective effects in animal studies.193 Thus the potential interaction 
between isoflurane and hypothermia cannot be ruled out, either beneficial or 
detrimental. Finally, we used the pH-stat approach for acid-base management, which 
considers the blood gas values at the patient’s temperature instead of standardizing it to 
37 ˚C (alpha-stat strategy). The pH-stat approach has been shown to result in improved 
neurological outcome compared to the alpha-stat strategy.194 However, such acid-base 
management leads to an acidic shift during hypothermia, which has been shown to 
decrease heart muscle contractility.195 
 To summarize, in our neonatal piglet model of HIE, we have demonstrated an 
abnormal metabolic homeostasis (lactic acidosis, hyperglycemia and hypokalemia), an 
increased need for volume replacement and inotrope support to maintain MABP, and a 
higher number of cardiac arrhythmias and fatalities with 30 ˚C deep hypothermia when 
compared to 33.5 ˚C or 35 ˚C. Subsequent analysis of mRNA responses and 




either provided no additional neuroprotection167 or even offered less protection than 
33.5 ˚C or 35 ˚C.122 These experiments, in combination with the negative results from 
recent clinical trials of 32 ˚C hypothermia 134 suggest that cooling to lower temperatures 
than the current clinical guidelines imposes significant risks while offering little or no 
additional benefit in neuroprotection. These findings have significant implications for 
neonatal care providers around the world, who are now adopting hypothermia as 
standard of care. 
 
7.2 Hypothermia and hypoxic hypometabolism 
 
Our experiments using a novel, non-invasive rodent model of HIE found that hypoxic 
hypometabolism is indeed present in the newborn rat and that it can significantly 
influence the tolerance to hypoxia. Even at ambient temperatures around 
thermoneutrality, the magnitude of the hypoxic hypothermia was highly variable and it 
greatly determined insult tolerance. After investigating the dose-dependence of insult 
tolerance to ambient temperatures, we found that maintaining a strict control of rectal 
temperature and adjusting ambient temperature in order to clamp the animal’s core 
temperature within the desired range was an effective strategy to minimize variability in 
hypoxia tolerance. However, the regulatory response to hypoxia could still be present, 
even though systemic hypothermia was prevented. Indeed, we should speculate that the 
animals were attempting to dissipate heat via peripheral vasodilatation (decreasing 
systemic vascular resistance) and hyperventilation, although these effects could not be 
directly observed in our setup. Such attempts could possibly impose an additional 
metabolic ‘cost’ for the animal and thus decrease its hypoxia tolerance to sub-
physiological values. However, this trade-off is unavoidable, since minimizing the 
effect of hypoxic hypometabolism by definition creates conditions which are different 
from extra-uterine hypoxia, naturally occurring in rodents. On the other hand, our 
experimental settings mimic the in utero conditions, where neonatal temperature is 
clamped at approximately 0.5 ˚C above the mother’s and the fetus has no options to 
dissipate heat.174 Hence, setting ambient temperature at 37 ± 0.5 ˚C and ensuring that 




physiological for postnatal rodents and more similar to human in utero asphyxia. 
 Such considerations have been largely missing from a number of animal 
experiments, potentially creating a significant confounder in these studies.163-165 
Looking back at clinical and preclinical approaches to temperature management, we can 
observe a rather converse situation. In the past, term newborns suffering in utero 
asphyxia were actively rewarmed and maintained at temperatures considered 
normothermic, but for these injured neonates during the first several hours of life, these 
temperatures could likely have been relatively hyperthermic.142 At the same time, 
preclinical models of HIE rarely cited hypoxic hypometabolism and endogenous 
hypothermia as potential confounders and offered no assurance that these effects were 
properly controlled.163-165 Thus not considering this evolutionary protective mechanism 
possibly led to working against it in certain clinical situations, as well as failing to 
compensate for it in preclinical experiments.  
 This bears great significance for both clinicians and scientists working with 
hypothermia and asphyxia, but also for other aspects of clinical care and research. 
Adopting such an evolutionary and physiological point of view can illuminate potential 
pitfalls and inadvertent detrimental effects. 
 
7.3 Creating translational models of HIE 
 
Similar to hypoxic hypometabolism, the fact that in utero asphyxia quickly leads to CO2 
retention and acidosis has been generally ignored in preclinical studies of HIE. Except 
for the models which closely mimic human pathology (such as the umbilical cord 
occlusion in fetal lambs196), most of the established experimental paradigms – including 
most adaptations of the widely used Vannucci-model – only employ exposure to 
hypoxia.24 Freely breathing animals in hypoxia can prevent CO2 retention by 
hyperventilation; and while subsequent hypoventilation and ischemia will increase 
pCO2, the dynamics and presumably the mechanism of injury is significantly different 
from human HIE. This was confirmed in studies by the Vannucci group itself, who used 
their established rodent model to investigate the effect of additional hypercapnia during 




concentrations of CO2 resulted in decreased neuronal injury up to a certain level, above 
which hypercapnia become deleterious.197 Since these results, however, most of the 
research groups using this model still conduct hypoxia without parallel hypercapnia. 
 The exclusion of hypercapnia and acidosis from the asphyxic injury is not the 
only aspect of the Vannucci-model which leads to translational difficulties. As discussed 
in the Introduction, in order to sensitize the forebrain to subsequent hypoxia, a 
permanent unilateral carotid artery occlusion is used in this model. Neither its unilateral 
nature, nor the mechanism of permanent ischemia preceding hypoxia have meaningful 
clinical parallels. A number of groups have previously attempted to address these issues, 
for example by extending the ischemia to two or four vessels,198 or using hypoxia 
only.199 However, none of these adaptations included concomitant hypercapnia/acidosis 
with hypoxia. 
 We have adopted the model developed by Prof. Kai Kaila’s group at the 
University of Helsinki.166 We have attempted to collaboratively characterize this novel, 
non-invasive rodent model of perinatal asphyxia, taking into account human 
pathophysiology and rodent physiology as well. The use of 4% O2 combined with 20% 
CO2 was also suggested by Prof. Kaila in order to achieve tissue gas concentrations 
similar to asphyxic neonates (unpublished results). Our preliminary experiments 
showed that using this gas mixture, 15 minutes of asphyxia at 37 ± 0.5 ˚C could be 
tolerated by P7 Wistar rat pups with < 30% overall mortality. Thus we began to 
characterize this novel model of birth asphyxia. 
 
7.4 A novel rodent model of birth asphyxia 
 
When characterizing a novel experimental model, it is necessary to conduct a large 
number of preliminary experiments first, using robust biomarkers in order to identify 
the major pathophysiological processes involved, which in turn should be investigated 
more thoroughly. This approach will inevitably lead to a large number of negative 
preliminary results and relatively few positive findings. The goal of these preliminary 
experiments is to guide further investigations, but they are not designed to confirm or 




conducted a number of investigations listed in the Methods section, which are not 
discussed in detail in the Results. The reason for this is that while we did not find 
indications about the sensitivity of these markers for our experimental paradigm, we 
cannot exclude this possibility with certainty. 
 These preliminary biomarker experiments included the screening of serum and 
urine samples for laboratory parameters potentially indicating changes in ionic 
homeostasis, kidney- and liver function. In connection to this we have also analyzed 
serum and tissue homogenate samples for inflammatory cytokine levels. The fact that 
neither of these approaches revealed significant effects of the asphyxia paradigm is in 
accordance with other preclinical studies using non-invasive methods of injury and 
resuscitation.166,199 Rodents in general are remarkably resistant to systemic injury. 
Multi-organ failure comparable to babies with severe HIE could only be elicited by 
extreme induction of inflammation.200 Similarly, histological markers did not reveal 
significant neuronal death or post-hypoxic necrosis in the brain of these animals. This 
also correlates well with findings from other models employing hypoxia alone199 as well 
as the early preclinical experiments in the ’60-s and ’70-s which showed that hypoxia 
without ischemia did not lead to significant histological damage.34 
 While we could not identify regions of major neuronal death, axonal injury, or 
white matter damage, we found an increased local inflammatory activation in the brain 
shortly after asphyxia. This activation was primarily localized in the hippocampus and 
the prefrontal cortex, both known to be sensitive to hypoxic injury.61 The fact that this 
inflammatory activation was not associated with immediate structural changes prompted 
us to investigate more functional consequences of this asphyxia paradigm. 
 In accordance with the lack of neuronal necrosis, gross neuro-motor function of 
these animals was not significantly affected by asphyxia, as evidenced by the Open 
Field, the Elevated Plus Maze and the Rotarod tests. However, we found an explicit 
phenotype of anxiety in the asphyxia group in the Elevated Plus Maze test. This result 
has been reproduced since and appears to be a stable outcome of this asphyxia 
paradigm.  
We have used the Operant Learning – Delayed Discounting paradigm to 
investigate more sophisticated neurological functions related to learning and 




two groups at all stages of the test. This means that both learning during the training 
phase and re-learning during the delay discounting phase was similar, corresponding to 
no overt differences in operant learning capabilities. However, when the increasing 
delay was introduced between the large reward response and the receipt of the reward, 
the asphyxia group reacted with a higher number of inadequate responses, indicating a 
phenotype of motor impulsivity. 
 These results are only the first steps in the characterization of this novel rodent 
model of perinatal asphyxia. However, together they suggest long-term effects of birth 
asphyxia on neurodevelopment, which are not due to direct and immediate cell death, 
but lead to a phenotype of increased anxiety and motor impulsivity. 
 
7.5 Relevance and limitations of these findings 
 
We have begun to characterize a novel rodent model of birth asphyxia in collaboration 
with Prof Kai Kaila’s group at the University of Helsinki, who originally developed this 
paradigm. This model encompasses many of the pathological features of in utero 
asphyxia, including clinically relevant O2, CO2 and Trec ranges. It resulted in acute 
inflammation in certain well-defined areas of the brain without overt neuronal death or 
systemic injury. When these animals were followed into adulthood, they showed a 
phenotype of anxiety and impulsivity, without neuromotor deficiencies. 
 The combination of anxiety and impulsivity is a characteristic of attention-
deficit/hyperactivity disorder (ADHD).201 ADHD is a multifactorial developmental 
disorder which usually presents itself in school-age children with an overall prevalence 
of approximately 2-3%.201 While its pathogenesis is largely unknown, epidemiological 
studies suggest that genetic as well as pre- and postnatal environmental factors are 
involved.201 Recent studies indicated perinatal hypoxia as a potential risk factor in the 
development of ADHD.202 
 As discussed in the Introduction, approximately 10% of all newborns require 
some form of assistance at birth and 1% need vigorous resuscitation, while only a small 
subset of these children will go on to develop neonatal encephalopathy.9 Thus, there is a 




but will not require intensive care and thus will not receive neuroprotective 
interventions such as hypothermia. It has been suggested long ago that if birth asphyxia 
is a continuous spectrum, then infants who die or suffer moderate to severe HIE must 
only represent one end of the spectrum and there should be a large group of neonates, 
who suffered relatively mild asphyxia.203 This group of infants is not seen in asphyxia 
trials and their first interaction with healthcare might be much later, when 
neurodevelopmental problems emerge. Recently there have been attempts to follow 
such large cohorts into childhood to prospectively determine the effects of perinatal 
factors. These cohort studies have employed stratification criteria based on Apgar-
scores,13,14 a need for resuscitation,15,16 or acidosis at birth.17 Their results have been 
equivocal, a few studies providing some level of confirmation to the theory of a 
continuous birth asphyxia spectrum,14,15 but the effect size of mild asphyxia appears to 
be rather low and of questionable clinical significance. However, we should note that 
these stratification criteria, such as the 5-minute Apgar score are generally poor 
predictors of outcome even in children with moderate to severe HIE, hence their 
usefulness in more complex and long-term neurodevelopmental disorders are probably 
rather limited. Unfortunately, we currently have no better means for designing such 
cohort studies and for stratifying patients. Hence the potential causative role of perinatal 
hypoxia probably has to be first elucidated in well-controlled animal studies. We 
propose that this novel rodent model of birth asphyxia originally developed by Prof. Kai 
Kaila’s group might be optimally suited for such work. It offers the possibility to 
identify neuroanatomical structures and functional connections specifically affected by 
mild perinatal asphyxia, the role of which could in turn be confirmed in human ADHD 
neuropathology. Even if these abnormalities can only be identified in later childhood, it 
would still offer the possibility to study the role of neuroprotective interventions on 
these deficiencies. These therapies could theoretically be applied around birth or 
possibly later on. However, without the means of definitive diagnosis at the time of 
intervention, these therapies will have to be designed as preventive measures, which 
benefit those in need of them, but does not impose a risk to others. One such therapy 
might be the restoration of normocapnia after asphyxia in a graded, instead of an abrupt 
manner.166 




inherently different structure than the human CNS. Additionally, as discussed in the 
Introduction, the optimal postnatal age for developmental comparison is unclear. We 
have chosen P7 animals largely to obtain results comparable to the most widely-used 
rodent models and to be able to identify model- and not age-specific differences. There 
are convincing arguments that a P10-12 rat might be more comparable to the term 
human newborn.204 Another important difference from human perinatal care is the lack 
of resuscitative efforts in this model. While our goal was to use minimal intervention, 
and intensive care would have required a number of significantly more stressful actions, 
there are other groups who are exploring these opportunities for translational preclinical 
studies with good results.205 Finally, extrapolating from rodent behavioral studies to 
humans is of course never straightforward, therefore our findings in this model will 
have to be confirmed in human patients. This is both the most challenging and the most 
promising aspect of our future work. 
 In summary, we have begun to characterize a novel, non-invasive rodent model 
of mild perinatal asphyxia. The animals surviving this insult showed localized 
inflammation in the brain without overt neuronal death, axonal injury or white matter 
damage. In adulthood, these animals displayed increased anxiety and motor impulsivity. 
This correlates well with the human phenotype of ADHD. These findings support 
previous epidemiological data suggesting a correlation between mild perinatal hypoxic 
events and neurodevelopmental impairments in later childhood, such as ADHD. This 
novel preclinical model might be instrumental in the future investigation of ADHD and 




8.  CONCLUSIONS 
 
Based on the work described in this thesis, the following conclusions can be drawn: 
 
1. Deep hypothermia to 30 ˚C poses a significant risk for systemic side-effects 
and offers no additional benefit in neuroprotection in neonatal hypoxic-
ischemic encephalopathy. Our results confirm that physicians now adopting 
therapeutic hypothermia should follow established treatment guidelines 
strictly, and carefully avoid inadvertent overcooling. 
2. Hypoxic hypometabolism and endogenous hypothermia are important 
confounders in a preclinical rodent model of birth asphyxia. In order to 
maximize translational value, researchers should take specific measures to 
avoid unintended hypothermia during hypoxia. 
3. This novel, non-invasive rodent model of mild perinatal asphyxia presents a 
neurodevelopmental and behavioral phenotype consistent with human 
ADHD-like symptoms. This paradigm could be valuable for developing a 
causal understanding between perinatal environmental effects and psycho-





9.  SUMMARY 
 
Neonatal hypoxic-ischemic encephalopathy (HIE) is one of the most severe diseases in 
the perinatal period. Establishing therapeutic hypothermia as standard of care for infants 
with moderate to severe HIE has been arguably the most important recent development 
in the field. As many clinical centers are now adopting this practice, questions about the 
optimal administration of cooling are increasingly pressing. While hypothermia is often 
viewed by clinicians as an artificial intervention, hypometabolism and endogenous 
hypothermia during and after hypoxia are well-researched evolutionary protective 
mechanisms in newborn mammals. Preclinical studies of HIE have also often failed to 
address these mechanisms, potentially incorporating a significant confounder. 
 Our first objective was to investigate the effects of deep hypothermia in a piglet 
model of HIE. We have found that 30 ˚C deep hypothermia led to significant metabolic 
derangement, circulatory compromise and cardiac arrhythmias, while offering little or 
no additional protection. Our results together with recent clinical trials suggest that 
current cooling protocols should be strictly followed and inadvertent overcooling 
avoided. 
 Our second objective was to observe the prevalence of endogenous hypothermia 
in a rodent model of HIE. We found that strict control of ambient temperature and direct 
monitoring of rectal temperature are both necessary to minimize the confounding effect 
of endogenous hypothermia in our rodent model. 
 Finally, we have begun to characterize a novel non-invasive rodent model of 
HIE, which incorporates many aspects of the human clinical condition, including 
hypoxia, hypercapnia, acidosis and normo- or mild hyperthermia. This model produced 
local inflammation in certain brain areas without overt neuronal necrosis, axonal injury 
or white matter damage. In adulthood these animals displayed anxiety and motor 
impulsivity. These phenotypes are consistent with the symptoms of human attention 
deficit/hyperactivity disorder (ADHD). Thus, our results support the potential causative 
role of perinatal asphyxia in the development of certain neuropsychiatric disorders in 
later life. We suggest that this novel translational rodent model of mild HIE might prove 




10.  ÖSSZEFOGLALÁS 
 
Az újszülöttkori hipoxiás-iszkémiás enkefalopátia (HIE) a perinatális életkor egyik 
legsúlyosabb betegsége. A közelmúlt legfontosabb eredményeinek egyike volt ezen a 
területen a hipotermiás terápia hatékonyságának igazolása és a kezelés beépítése a 
klinikai protokollokba világszerte. Ahogy napjainkban egyre több ellátóhely alkalmazza 
ezt a kezelést, a hűtés optimális módjával kapcsolatos kérdések is egyre inkább az 
érdeklődés középpontjába kerülnek. Ugyanakkor a legtöbb klinikus jelenleg is 
mesterséges beavatkozásként tekint a hűtésre, miközben újszülött emlősökben a 
hipometabolizmus és az endogén hipotermia jól ismert és evolúciósan konzervált 
protektív mechanizmusok. Hasonlóképp, a HIE-vel foglalkozó preklinikai vizsgálatok is 
általában figyelmen kívül hagyták ezeket a protektív mechanizmusokat, amelyek 
ugyanakkor komoly zavaró tényezőt jelenthetnek az eredmények értelmezésekor. 
 Kutatásunk első célkitűzése a mély hipotermia hatásainak vizsgálata volt a HIE 
újszülött malac modelljében. Eredményeink azt mutatták, hogy a 30 ˚C-os mély 
hipotermia jelentős metabolikus zavarokat, keringési instabilitást és kardiális arritmiákat 
okozott, miközben legfeljebb minimális additív hatása volt a neuroprotekció terén. Ezen 
eredmények a közelmúltbeli klinikai vizsgálatokkal együtt alátámasztják a jelenlegi 
hűtési protokollok szigorú követésének és a véletlen hipotermia elkerülésének 
jelentőségét. 
 Második célkitűzésünk az endogén hipotermia előfordulásának vizsgálata volt a 
HIE rágcsáló modelljében. Eredményeink azt mutatták, hogy mind a környezeti 
hőmérséklet szigorú szabályozása, mind a rektális hőmérséklet szoros követése fontos 
az endogén hipotermia hatásának minimalizálásához. 
 Mindezek fényében kutatócsoportunk megkezdte a HIE egy új, non-invazív 
rágcsáló modelljének jellemzését, amely tükrözi a humán kórkép számos aspektusát, 
úgy, mint a hipoxia, a hiperkapnia, az acidózis és a relatív normo- vagy hipertermia. 
Ebben a modellben az aszfixia rövidtávon lokalizált agyi gyulladáshoz vezetett, amelyet 
nem kísért jelentős neuronhalál. Felnőtt korukban azonban az aszfixiás állatok 
szorongás és motoros impulzivitás fenotípusait mutatták, neuro-motoros diszfunkció 




hiperaktivitás-zavar klinikai tünettanában. Eredményeink tehát alátámasztják a 
feltételezést, miszerint perinatális hipoxiás ártalmak oki szerepet játszhatnak bizonyos 
gyermekkori neuro-pszichiátriai kórképek kialakulásában. Az enyhe HIE ezen rágcsáló 
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